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Abstract 
Lipid based non-viral delivery systems are potentially of great 
importance to the development of an effective and versatile therapeutic 
gene treatment. Many difficulties are faced in designing efficient lipid 
based gene delivery systems and addressing the problem of endosomal 
escape is one key area where efficiency could be greatly improved 
Molecules aimed at inducing aggregate disruption in response to 
changes in pH, or metal ion concentration, have been synthesised. Series 
of compounds were prepared based on cationic 5-alkyl-2-
methylaminoalkyl pyridine amphiphiles and amphiphilic Cs-C15 EDTA 
dialkylamides. 
The critical aggregation concentration of each species was 
measured and a series of experiments undertaken, designed to assess 
the extent of pH, or metal ion concentration, induced aggregate 
disruption effects. The experiments were carried out by including the 
molecules to be examined as small mole percent eo-aggregates in 
micellar and liposome model systems. 
Each group of compounds appears to exhibit disruption effects on 
the more strongly ordered bilayer membrane systems, with the EDTA 
based compounds displaying the most consistent pH dependent 
disruption. However, the more dynamic micellar aggregate models were 
less sensitive to disruption using the particular observation method 
employed. 
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Chapter 1 
1 Introduction 
After a brief introduction to the area of gene therapy and in 
particular gene delivery, this chapter addresses problems encountered 
by synthetic lipid based delivery systems. The work presented in this 
thesis is aimed at overcoming one of the problems encountered by 
synthetic transfection systems, namely the controlled destabilisation of 
an endosome vesicle or related aggregate structures. 
Gene therapy is the use of genetic material from an external 
source to express a protein or peptide which will have a beneficial 
effect on a patient's condition. The conditions which are treatable 
could be inherited genetic disorders or acquired conditions which will 
be relieved by the production and release of a specific protein. There 
is, therefore, great potential for gene therapies to eliminate diseases 
such as cystic fibrosis, diabetes and other conditions which are 
believed to arise from the failure or absence of a specific gene. There 
is also scope for the treatment of cancers, by using targeted gene 
therapies to slow cell division, reverse mutations which cause tumour 
growth or cause the targeted tumour cells to die. This large number of 
potential applications along with the serious nature of many of the 
conditions potentially treatable has made gene therapy a widely 
researched area, as teams around the world strive to produce efficient 
and safe methods for gene therapy. 
With the completion of the first draft of the human genome 
project in 2000 1, the increasing ease of DNA synthesis, and the 
function of more and more genes being identified, the production of 
appropriate therapeutic genetic material is rapidly becoming the least 
of a gene therapist's worries. Gene delivery, however, is the key to 
effective gene therapy and is still a problem which has to be faced and 
overcome before the envisaged "magic bullet" gene treatments can 
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become a reality in everyday clinical use. At present, the few gene 
therapies in clinical use, whilst having some observable effect, do not 
represent efficient treatments for any human disease. 
Gene therapy systems are based on a wide range of delivery 
routes and strategies, some of the most commonly used and 
researched, along with the main problems which they encounter are 
discussed in the following pages. 
1.1 Gene Delivery 
1.3.1 DNA/RNA 
DNA or RNA is the core of every gene delivery vehicle. Both 
molecules are large polymeric molecules made up of a phosphate 
linked strand. From this strand deoxyribose (DNA) or ribose (RNA) 
sugar moieties are appended. Each DNA sugar unit carries one of four 
heterocyclic bases adenine, guanine, thymine and cytosine (Figure 1). 
In RNA, thymine is replaced by uracil, a similar structure to thymine 
but lacking the methyl group on the ring. 
DNA and RNA strands can link via hydrogen bonds, forming a 
double stranded structure. DNA is normally found as a double strand 
which can adopt a number of conformations. The most famous and 
more common conformation in vivo is the double-helix. The structure 
of DNA allows for the encoding of information through different 
arrangements of the four bases. This information when decoded 
through the binding of RNA in a process known as transcription, leads 
to the production of proteins, pep tides and ultimately the construction 
and maintenance of complex multi-celled organisms. RNA is usually a 
single strand polymer which binds to DNA in the transcription 
process. The DNA and RNA molecules are susceptible to degradation 
in acid conditions and digestion by the action of nuclease enzymes. 
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Figure 1 DNA Structure 
Base structure labels 
A=Adenine T=Thymine G=Guanine C=Cytosine 
The charges along the phosphate linked 'backbone' of the DNA 
repel each other and this electrostatic influence increases the size of 
the DNA molecule as well as playing a part in determining the 
conformations adopted by the double strand systems. The size of the 
DNA molecule is a major factor which needs to be considered before 
delivery systems can be designed. Large molecules are difficult to 
carry across cell membranes and may even become trapped in narrow 
blood vessels. Neutralisation of the phosphate charges by cationic 
species, such as spermine and related polyamines, allows compaction 
10 
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of the DNA structure2·3 ·4 . These species are important in the design of 
systems to allow the transport of DNA through the body. 
1.2 Transfection and Expression 
Transfection and expression are the key goals for gene delivery. 
Transfection is the crossing of the cell and nuclear membranes and 
release of the new genetic material to be expressed by the cell. 
Expression is the action of the DNA being transcribed into a protein. 
However this process is not one which occurs easily and 
spontaneously with any great efficiency. Some of the underlying 
difficulties faced in trying to achieve effective transfection are detailed 
below. 
1.3.1 Barriers to be Crossed 
There are several'barriers' to achieving transfection and 
ultimately expression of genetic material within a cell. In general, the 
human system has evolved over thousands of years to prevent the 
damage and alteration of the genetic material at the core of every cell. 
These highly evolved survival mechanisms which reduce mutations 
and try to prevent the inclusion of foreign DNA into the human 
genome, pose significant obstacles to the inclusion of therapeutic 
genetic material and therefore to gene therapy5 . These barriers can be 
separated into two categories: extracellular barriers and intracellular 
barriers6. Intracellular barriers, apart from the obvious and physical 
barrier of crossing the cell membrane, include instability of DNA in the 
cytoplasm, DNA escape from endosomes and the resulting degradation 
of DNA in the lysosome if this is not achieved. Translocation of DNA to 
the nucleus once inside the cell, is another intracellular obstacle. 
Extracellular barriers are linked with systemic survival, targeting and 
administration routes. DNA is degraded or cleared from the system 
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rapidly by blood plasma and trapped by the capillary beds found in 
the reticuloendothelial system. The oral administration route is 
almost completely ineffective and transfection of cells within the body 
is suppressed by mucosal coatings found in various tissues. If not 
addressed, each of these obstacles will reduce the level of expression 
and if several of these barriers are not effectively addressed then they 
can quickly reduce the levels of transfection and expression to zero. 
1.3.2 Transport and Protection 
DNA is susceptible to attack and degradation by nuclease 
enzymes as well as acidic environments encountered within the 
human system. In order for destruction or mutation of the therapeutic 
DNA to be averted, exposure to any of these environments must be 
avoided. To prevent damage during transport through the body and 
so increase the transport range of DNA, gene therapy systems almost 
always employ some form of protective coat to the genetic material. 
This varies from proteins to lipids 4 ·6 ·7 and even inorganic layered 
clays8 . 
These coatings allow the possibility of overcoming another 
transportation barrier, the targeting of gene therapies. Effectively, 
targeted gene therapy agents could be administered in lower doses 
and would produce fewer unwanted side effects as less 'chance 
expression' would occur. 
Targeting generally relies on the recognition of receptors or 
other features on the target cell's surface. By adding moieties which 
bind these receptors or recognise proteins present on specific cell 
surfaces, the uptake of the delivery vehicles by that cell type can be 
increased. If the receptor also triggers the intemalisation of the 
delivery system, a secondary advantage can be received. Targeting 
can also be achieved on a physical, macro-scale basis by the injection 
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or delivery of the gene therapy agent only to the target tissue. This 
direct injection approach of tissue targeting has become increasingly 
viable as development of 'keyhole' surgical techniques has allowed 
accurate and direct access to the internal organs without the need for 
highly invasive surgery. (See section 1.3.3). 
1.3.3 Endocytosis 
Endocytosis is the natural mechanism by which cells internalise 
any large particle which cannot diffuse across their membrane9. The 
mechanism can be triggered by molecules binding to specific receptors 
on the cell surface, or can be a more spontaneous process when 
particles fall into preformed pits on the membrane surface (Figure 2.) 
In each case the steps of the mechanism are almost identical. In the 
early stages of endocytosis, the particle to be internalised binds to the 
receptor or enters the pit on the cell membrane's surface. In the 
receptor mediated case, binding initiates the process of pit formation. 
The pit then begins to deepen and the outer edges of the pit close 
together over the particle encapsulating it within a pouch attached to 
the cell membrane. This pouch pinches off from the inner wall of the 
cell to become a free 'mini-cell' or endosome containing the particle. 
13 
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Particle binds to receptor on cell surface. 
Figure 2 
Pit formation 
triggered by 
binding 
Cell membrane 
reforms, enclosing the 
particle. 
Enveloped particle buds away 
from cell membrane. A free 
endosome is formed. 
Diagram showing particle intemalisation by receptor 
mediated endocytosis 
1.3.4 Endosomal Properties 
Due to their small size, endosomes lack the proteins which act 
as channels and 'ion pumps' through cell membranes to maintain 
constant concentrations of various ionic species. In particular, 
endosomes lack the ability to maintain pH at the usual physiological 
levels. As a result of this, endosomes begin to acidify from the moment 
they become separated from the cell membrane9. Endosomes acidify 
from their initial ambient physiological pH of 7.24. The pH within the 
endosomal compartment drops to as low as pH 4 as the endosome 
ages and moves into the cell. In addition to the change in pH, the lack 
of active transport across the endosomal membrane results in 
increased metal ion concentrations [Mn+], particularly levels of Ca2+ 
and Zn2+ are thought to increase. Endosomal packages often fuse 
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with other endosomes within the cell, as they age. Eventually these 
ageing endosomes fuse with, or develop into lysosomes. These 
structures are larger cellular organs which contain not only an acidic 
environment but also digestive enzymes. Lysosomes can be thought 
of as cell stomachs. The lysosome breaks down the particle brought 
in via endocytosis and recycles any useful nutrient constituents into 
the cell's metabolism. 
1.3 Delivery Systems and Strategies 
1.3.1 Viral Delivery 
Viruses are the benchmark for targeted DNA delivery. With 
millions of years of evolutionary development behind them, they have 
routes to effectively move through their host, enter its cells and deliver 
their own genetic material to the nucleus of those cells for 
expression 1 o. The structure of viruses varies greatly between the 
different classifications and is usually linked to the target host's 
biology and the type of genetic material5 . Viruses are based on 
proteins which form the protective coating for the DNA, known as the 
capsid (Figure 3). Viral capsids come in various shapes and can 
contain structures to aid cell recognition and mechanisms to 
stimulate cell entry and release of their cargo of genetic material. 
Some viruses make use of the cell membrane of their last host as an 
extra layer of protection around their capsid9. These enveloped viruses 
make use of their outer membranous coating as a means of gaining 
entry to their next host cell via membrane fusion. 
15 
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Human adenovirus 
(icosahedral) with the fibres 
involved in cell binding and 
recognition visible 
Micrographs of human 
paramyxovirus which 
causes mumps. 
Figure 3 
structures 11 . 
Diagrams and micrographs showing different viral capsid 
Research into viral gene delivery vectors makes use of highly 
infectious virus types: retroviruses which carry RNA and of which HIV 
the human immunodeficiency virus is a member, adenoviruses which 
include the common cold and herpes based viruses 12,13. 
The viruses to be used as vectors have their original DNA 
replaced or deactivated and the therapeutic strand inserted. In order 
to then produce large quantities of the therapeutic agents, cell 
cultures are infected with the virus and used to produce large 
numbers of replicated genetically modified viruses14 . The major 
issues facing the use of viruses therapeutically, are the response of 
the immune system in vivo to the presence of the viral proteins, as 
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well as receptors on the viral surface. This response reduces the 
efficiency of treatment in patients who may have encountered the 
strain of virus hijacked for the therapy. As well as this potential for 
existing resistance, there is the problem of the active immune system 
of a patient creating a resistance and reducing the effectiveness of 
subsequent treatments using that viral gene therapy agent. This 
problem could be overcome using immune suppression treatments in 
parallel but the benefits of the gene therapy would need to be 
significant and proven to justifY such a drastic treatment. 
In addition to resistance, problems can be envisaged with 
incomplete deactivation or replacement of the original viral genetic 
material. In these circumstances, patients could contract the original 
virus. This could be serious if the patient was already in a weakened 
condition, or if immune suppression were being used to prevent the 
problems of resistance to the viral gene therapy. 
Viruses are effective transfection systems which are used 
successfully in ex vivo treatments and show high activity in in vitro 
experimentsl2,13,15,16. Some viral strains make use of endocytotic 
pathways to enter the cell and have evolved mechanisms which 
respond to the changing conditions within the endosome to trigger 
release into the cytoplasm. Certain viruses have also evolved methods 
of hijacking the natural systems within the cell to transport their 
genetic material to the nucleus, although others replicate and express 
their DNA in the cytoplasm. 
1.3.2 Synthetic Vectors 
Synthetic vectors encompass a range of different strategies for 
protection and delivery. These systems can be based on polymers, 
liposomes, or polypeptides and proteins. Each of the systems lacks 
the complete package offered by viral systems, but each has the 
advantage of not triggering an immune response, or posing an 
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infection risk, although immune recognition could be an issue with 
protein based systems. Another advantage of synthetic systems is the 
potential ease of their production. Viral vectors require the use of cell 
cultures in their production and this leads to higher cost and greater 
difficulty in producing precisely reproducible results. 
1.3.3 Polymer Delivery Systems 
Polymer based delivery systems most commonly consist of 
cationic polymers which interact electrostatically with the negatively 
charged phosphate backbone of DNA. The polymers bind and 
compact DNA, giving protection from the hazards encountered during 
delivery and reduce the size of the DNA molecule allowing easier 
transport and cell entryl 7.l8.l9 .20. Straight chain and branched 
polymers have been used, as have dendrimers21 , block co-polymers 
and grafted co-polymers 22·23·24• All polymer systems give the 
opportunity of attaching targeting ligands which are designed to bind 
to specific features on the cell surface, maximising contact time and 
stimulating internalisation by receptor mediated endocytosis25. 
Figure 4 Structure of poly(L-lysine) at pH 7.4 
Poly(L-lysine) (PLL) (Figure 4) is the oldest example of a polymer 
delivery system. This polymer has been shown to have the ability to 
18 
Chapter 1 
form a complex that protects DNA from attack by nucleases. It also 
leads to significant transfection ability in vitro when used with 
endosomolytic agents such as chloroquine. (Figure 5}. Chloroquine is 
thought to act as a buffer to the pH drop within the endosome and 
may also act to destabilise DNA complexes with polycationic 
species7.26. PLL also shows activity when modified with targeting 
ligands. However, the significance of these observations is moderated 
by the high percentage of cell death in the in vitro experiments and the 
short in vivo circulation half life observed with rodents27 . Lower 
molecular weight PLL systems, which show no toxic effects to cells, 
also show little or no transfection activity and a reduced ability to 
protect their bound DNA7. 
Cl 
Figure 5 Structure of chloroquine (p.Ka 8.4 and 10.826) 
Polyethylenimine (PEI) (Figure 6} based systems have proved 
more efficient delivery systems than PLL as they do not require 
endosomolytic agents in order to have transfecting abilities2 8.29. This 
is thought to be due to protonatable amine groups present on the PEI 
chains. PEI efficiency is also affected by molecular weight, although 
some literature sources differ as to what those affects actually are 6,29. 
Despite advantages over PLL, PEI does however share some of the PLL 
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associated toxicity problems and hence is unlikely to be used clinically 
unless these issues can be addressed properly. 
Figure 6 Structure of branched polyethylenimine (PEI). The level of protonation of the 
amine groups is -20% at pH 7 and -50% at pH 5; straight chain and more 
highly branched structures are also possible 
Biodegradable polymers may offer a balance between toxicity 
and transfection ability. The main problem which is faced by 
researchers designing biodegradable polymer delivery vehicles is in 
striking a balance between the time taken for the polymer to decay, 
once transfection has occurred, and the stability of the polymer 
structure to both intra and extracellular environments30.3l. The 
breakdown of biodegradable polymers within the cell, can prevent the 
build of potentially damaging polymer molecules, which can lead to 
cell death via membrane damage. The action of polymer degradation 
may also help to increase the expression of the therapeutic DNA, by 
promoting the release of any genetic material complexed by the 
polymer, either within the endosome or cytoplasm. Polymer systems 
can also make use of the pH change which occurs within the 
endosomal compartment22,32, as this is the route thought to be 
followed to gain cell entry. These pH sensitive polymers, which 
include PEI and polyamidoamine systems, are thought to operate by 
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the 'proton sponge' mechanism. The multiple protonation presumably 
triggers an influx of counterions and subsequently water, causing 
osmotic swelling and eventually endosome rupture, followed by release 
of the polymer-DNA complex into the cytoplasm. If increased stability, 
reduced toxicity and good targeting features can be built into 
polymeric systems which bind and compact DNA, then an effective 
and versatile therapeutic vector could be synthesized. 
1.3.4 Lipid Vectors 
Cationic lipid based vectors allow for a range of different 
approaches to gene delivery depending on lipid structure and 
formulation of the final delivery vehicle33,34,35. Liposome based 
systems encapsulate compacted DNA inside vesicles with bilayer 
membranes7 • Lipoplexes (lipid complexes) are formed by lipid 
molecules incorporating DNA binding moieties. Lipoplexes can form 
systems with a functionallised 'tail', or the charged (cationic) 'head' 
surface of the lipid binding to the DNA36,37 . There are a wide range of 
variations in structure and formulation of lipid based vectors. This 
allows for optimisation of transfection ability, stability and cell 
specificity to be attempted, by modifying the structure of the lipid 
molecules used, or by combining mixtures of lipids to achieve a 
specific property7.38,39. Lipofectin is a commercial transfection product 
for in vitro delivery which uses a 1:1 mixture ofN-[1-(2,3-di-
olyloxyproyl]-N,N,N-trimethylammonium chloride: 1,2-
dioleoylphosphatidylethonolamine ( or DOPE). One of the lipofectin 
components, DOPE, has been used independently in gene delivery 
research40.41. DOPE is believed to facilitate membrane fusion during 
transfection and has been used in combination with many other 
lipids. It has also been modified to include pH cleaved moieties which 
are removed at late endosomal pH42, thereby allowing the fusogenic 
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properties of DOPE to take effect only when the delivery vehicle is 
within the endosome and acid cleavage has taken place (Figure 7). 
0 
CDOPE 
DOPE 
Figure 7 Structures of N-citraconyl-dioleoylphosphatidylethanolamine (CDOPE) and 
dioleoyl phosphatidylethanolamine (DOPE)42. 
Previous research carried out, within the group at Durham and in 
association with the biotechnology company Celltech plc., led to the 
design and synthesis of a novel amphiphilic bola-lipid based delivery 
vehicle which contained multiple amine groups in a double tail for 
DNA binding (Figure 8) and formed toroidal lipoplex particles with 
radii of -41-50nm (measured by photon correlation spectroscopy and 
a combined field-flow fractionation and multi-angle laser light 
scattering method) when condensed with DNA43. The aggregate 
bolasomes were stable from pH 3.5- 7.5 and resisted attack from 
DNAse I and Protease XIV (37°C, pH 7.4.). The formulation of this lipid 
delivery system was found to have a significant effect on the 
transfection ability of the vehicle. The formulation with the highest 
transfection ability, contained a mixture of the polyethylene glycol 
(PEG) modified amphiphiles and the amphiphiles with the sugar head 
group. 
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!Figure 8 Examples of Bola-amphiphile molecules43 
This use of PEG groups in gene delivery vehicles is widespread. 
PEG groups are known to reduce transfection in vitro. However, during 
in vivo studies with both polymer and lipid systems, it has been found 
that inclusion of PEG units reduces the trapping of delivery systems 
in the lung tissue6. This allows longer circulatory lifetimes and 
increases expression in the liver. The use of ligands or antibodies and 
PEG groups in delivery systems shows more effective ligand mediated 
targeting. 
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1.4 Administration routes 
1.3.1 Ex-Vivo 
The ex vivo route involves removal of cells from the patient, 
followed by incubation of those cells with a gene delivery vector, to 
produce a line of genetically modified cells, which are then returned to 
the patient's system5. This route is normally associated with blood 
cells as they are the easiest to remove and replace. 
1.3.2 Intravenous injection 
Intravenous injection is the administration route aimed for by 
most of the liposomal species, viral systems and polymer /peptide 
complexes. Each of these systems attempts to stabilise and protect 
their DNA cargo for transport through the blood stream. However, at 
present, a system which offers effective targeting, sufficient stability 
and low toxicity has yet to be designed. Most in vivo trials of gene 
delivery systems show low expression, with most activity occurring in 
the lung epithelium where the vectors are 'filtered' out of the 
bloodstream6 • Use of targeting ligands has been successful to a 
certain extent but, in many cases, just leads to the site of activity 
being moved to the liver. 
1.3.3 Injection into tissue 
This can be intramuscular, subcutaneous or directly into any 
accessible tissue. This delivery method is becoming more flexible as 
keyhole surgery techniques and endoscopic techniques develop. These 
techniques allow more organs and areas of the body to be accessed for 
injection. The DNA formulation to be injected could be 'naked' DNA 
(simply a solution of plasmid DNA with no other species bound or 
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associated with it). 'Naked' DNA has little or no transfection ability in 
vitro but has shown some activity through in vivo studies when 
injected into solid tissues, such as smooth muscle6. Interestingly, 
application of more complicated delivery systems, in many of these 
cases, shows no improvement over naked DNA and, in some 
instances, even reduces transfection. Researchers report that there is 
also little diffusion from the site of administration for naked DNA, viral 
or synthetic delivery vectors, when injected into solid tissue44. This 
localisation of action, means that targeting of the therapeutic agent 
can be achieved physically and without the need for complex 
modifications to the formulation, for each site or tissue type. Using 
surgical techniques, this type of application has also shown success in 
the liver45. Clinically, intra-muscular injection has been assessed in 
DNA vaccination studies, where genetic material coding for a specific 
antibody is implanted to give instant immune response to a specific 
pathogen. Injection into solid tissue has been combined with 
electroporation to improve gene uptake. Electroporation increases the 
crossing of the cell membrane by the application of a current through 
the tissue. This encourages pore formation in the cell membrane and 
makes cell entry, for larger particles, possible. 
1.3.4 Inhalation 
This route of administration has been successful when used 
with lipoplex transfecting agents. The delivery system is formulated as 
an aerosol and has been tested as a treatment for cystic fibrosis, 
although there are currently no licensed gene treatments available6,46. 
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ll..5 Lipid Systems 
ll.3.1 Aggregates, Surl'actants, Amphiphiles and Micelles 
Many different molecular types form aggregate structures in 
solution. These molecules can be classified as surface active agents or 
surfactants. All surfactant systems are amphiphiles, having both 
lyophilic (or liquid/solvent loving) and lyophobic sections (or liquid/ 
solvent hating). For aqueous surface activity, an hydrophobic section 
and an hydrophilic section is required. Amphiphile molecules can be 
non-ionic, anionic, cationic or amphoteric but they share the same 
basic structural properties. Some examples of common surface active 
molecules are shown in Figure 9. All surfactant molecules share 
certain properties in solution. In dilute solution they behave as 
normal solutes and, in the case of ionic systems, the expected 
electrolyte properties are observed. At well defined concentrations, 
however, distinct and easily observed changes to a number of the 
solution's physical properties take place. These properties include 
surface tension, conductivity, turbidity and osmotic pressure. This 
behaviour has been explained in terms of the formation of organised 
aggregates, or micelles, of the surfactant molecules. The lyophobic 
groups associate and orient into the centre of the aggregate away from 
the bulk solvent and the lyophilic groups remain solvated at the 
surface of the aggregate. 
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Figure9 Common examples of ionic, non-ionic and amphoteric surfactants 
The concentration at which the aforementioned properties change, is 
defined as the point at which micelle formation becomes appreciable 
in solution and is termed the critical micelle concentration or CMC47. 
Micelle formation can be thought of as one of four dynamic equilibria 
occurring in the surfactant solution. The first of these equilibria, is 
the dissolution of the surfactant from the solid state into free solution. 
Once in solution, the molecules enter into an equilibrium with 
micellar vesicles in solution. There are also equilibrium processes 
between the surfactants in solution and the solvent I atmosphere 
interface. For completeness, the final equilibrium possible between the 
solid phase and surfactants adsorbed to the solvent I atmosphere 
interface should also be included. The stability of these aggregate 
systems is dependent on the structure of the surfactant molecule, as 
well as physical conditions such as temperature. 
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a) Micelles 
The structure of micelles has been the topic of much debate. 
Several models have been proposed; a spherical system, a rod like 
structure and a lamellar structure. Many variations of the definitive 
structure, or the combination of structures likely to be present in 
micellar solutions, were suggested. With the use of various 
techniques, from NMR and ESR to light and neutron scattering, the 
structure is now thought, however, to change with increasing 
concentration. The initial structure is spherical, with a relatively 
disordered interior in which the hydrophobic alkyl chains are not in a 
regular array. As the concentration is increased, the micelle shape 
becomes rod-like with rounded ends. This structure packs into an 
hexagonal array and eventually an infinite lamellar phase (Figure 1 0), 
although some surfactant types may skip a phase48. 
(a) 
(b) (c) 
(d) 
Figure 10 Schematic representation of amphiphile aggregation structures. (a) 
Spherical Micelle, (b) Cylindrical, (c) Hexagonal, (d) Lamellar 
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Liposomes are more stable, bilayered aggregate structures, 
which completely enclose a volume of solvent49 . They are most 
commonly formed by twin tailed surfactant molecules, specifically 
phospholipids such as DMPC Figure 9. These phospholipid molecules 
occur naturally in the wide array of biological membranes and have a 
number of different structures and features. Because liposomes can 
be formed which closely resemble cell membranes, they are useful, not 
only as models of biological bilayers, but also in the transportation 
and protection of sensitive molecules and preparations through 
biological systems, as in the case of DNA delivery. 
lL .3.2 Aggregate Effects 
The aggregate structure creates environments differing greatly 
from those found in a dilute solution. Molecules within these 
environments exhibit properties specific to the environment type 
encountered. The polarity and polarisability differ between 
hydrophobic and hydrophilic areas. These effects mean that some 
small molecules, which can be trapped or associated with either of the 
different environments created by the aggregation of the amphiphile 
molecules, have their physical properties affected. This effect can be 
used to observe aggregation by using molecules, easily observed 
spectroscopically, which have their spectroscopic properties altered by 
the environment in which they find themselves. Fluorescent molecules 
are used as probes, to determine CMC in micellar systems and to 
detect breaches in liposome membranes. eo-aggregates are formed 
when two or more different amphiphiles, usually of the same type; 
cationic and cationic, non-ionic and non-ionic, associate to form a 
well-defined aggregate structure. The distinguishing properties of eo-
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aggregates differ from each of the components. The CMC of a binary 
eo-aggregate. usually lies between the CMC's of its components48. 
1.6 Controlled Disruption of Aggregates 
ll. .3.11. Methods of dismption 
Aggregate structures can be disrupted by the addition of various 
substances to the aggregated solution. Adding molecules which alter 
the solvent polarity or adding differently charged surfactant molecules 
or amphiphiles of a different structure to the initial aggregate system 
can cause disruption of aggregates already in the solution. For 
example, adding cationic liposomes to anionic liposomes causes a 
reorganisation of the membrane structures and the release of the 
liposome contents50. 
Several systems have also been devised in which amphiphile 
molecules in the aggregate react to change their aggregation 
properties. These systems respond to the solution environment or to 
external radiation to alter the aggregative properties of the surfactant 
molecules and cause disruption to the aggregated structure. The 
remainder of this section deals with such 'internal' disruption systems 
separated into categories by the conditions which trigger their action. 
a) Redox Sensitivity 
There are a small number of examples of lipid systems which 
are destabilised following exposure to reducing conditions 51.52.53. The 
active groups within the lipid or lipopolymer chain, tend to be 
disulfide linking functionalities. The reduction sensitive lipid cleaves 
at the disulfide bond, altering the chain length of the amphiphile, 
and/ or the charge distribution within the aggregate, causing the 
system to be destabilised. Disulfide links will however degrade in 
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ambient biological conditions over time and so the stability and 
targeting efficiency of these reduction sensitive formulations is called 
into question. 
b) Optical Switching 
A number of different systems have been designed which make 
use of radiation from NIR through the visible to UV, in order to trigger 
release from liposomes54,55,56. The systems make use of either small 
mole percent additions of a sensitive amphiphile to the membrane or a 
membrane completely made up of lipids which are engineered to 
respond to the radiation applied. The strategies employed to bring 
about destabilisation are photo-induced polymerisation or 
dimerisation57,58 of lipids in the membrane, photoionisation often 
within the hydrophobic environment of the aggregate structure and 
optically switched isomerisation59,60. Work carried out by Ohya et a159 
synthesised a cationic amphiphile molecule carrying the 
photosensitive spiropyran group as the terminal functionality of the 
hydrophobic tail section. On irradiation, the spiropyran undergoes 
isomerisation to its zwitterionic merocyanine form inducing a charged 
hydrophilic centre at the chain end. Liposomes prepared containing 
the spiropyran amphiphiles at 5-l 0 mole percent levels showed 
leakage triggered by irradiation at the correct wavelength (465nm) 
thought to be caused by reorientation of the photosensitive lipids 
within the membrane. Each of the strategies mentioned above aims to 
cause movement within the membrane and a localised reorganisation 
of the aggregate, thereby allowing release of the aggregate contents or 
complete disruption of the aggregate structure. 
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c) pH/pM 
There are a number of published examples of systems which 
respond to changes in solution pH 61,62.63,64.65. A series of 
amphipathic molecules with protonatable functionality (pKs in the 
range 5-8 Figure 11) in the 'head' group have been studied. These 
molecules have been combined with DOPE to form cationic liposomes 
and DNA liposome complexes. The liposomes and complexes have 
been shown to exhibit significant pH sensitive fusion properties and 
increased transfection ability when used in in vitro transfection 
experiments 5 6 . Biodegradable pH -sensitive surfactants have also been 
investigated for use in the disruption of liposome systems. (e.g. 
dodecyl 2-(1-imidazoyl) propionate) they are related to lysosomotropic 
detergents which are known to disrupt phospholipid bilayers and are 
able to concentrate within intracellular acidic compartments. These 
species are lipophilic amines with pKa values between 5 and 9. On 
protonation their surface activity is enhanced leading to membrane 
disruption. DNA liposome complexes containing dodecyl 2-( 1-
imidazoyl) propionate in the membrane have been shown to have 
significantly increased transfection ability when used in vitro for gene 
transfer67 . The proliferation of research in this area is linked to the 
potential of such systems to be triggered by the natural pH drop 
within an ageing endosome. If systems which make effective use of 
this drop in pH can be formulated, then lipid based gene delivery or 
drug delivery systems which make use of an endocytotic route to gain 
cell entry may become significantly more efficient by responding to the 
natural environmental changes only encountered during 
intemalisation. 
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Figure 11 Structures of some pH sensitive lipid molecules66 
DPim: 4-(2, 3-bis-palmitoyloxy-propyl) -1-methyl-1 H-imidazole, 
DOim: 4-(2,3-bis-oleoyloxy-propyl)-1-methyl-1 H-imidazole, 
Chlm: cholesterol-(3-imidazol-1-yl propyl) carbamate, 
DPAPy: 2,3-bis-palmytoyloxy-propyl-pyridine-4-yl-amine. 
1.3.2 Focus of Experimental work 
Chapter 1 
The systems investigated in this thesis have been designed to 
destabilise micellar or liposomal systems when triggered by a pH 
change, consistent with that occurring within the endosome following 
endocytosis. The work has focussed on two strategies to achieve 
destabilisation one of which has the potential to be effected by a 
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change in metal ion concentration as well as pH. This may also be a 
useful trigger as the concentration of certain metal ions, most notably 
Ca2+ and Zn2+ is reputed to change within the ageing endosomal 
compartment. The following chapters describe the system design, the 
synthetic work carried out in the realisation of that design and the 
analysis undertaken once the molecules under investigation were 
synthesised. 
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~. Jl System StJrategy 
A strategy based on the protonation of a single chain cationic 
amphiphile molecule containing a protonatable functionality 
approximately half way down the hydrophobic tail section was 
hypothesised. The molecules are proposed to be used as an additive 
to form eo-aggregates with cationic lipids. The additive species being 
designed cause destabilisation upon lowering pH, leading to aggregate 
disruption. The aim of including and positioning this protonatable 
functionality mid-chain was to introduce a charge centre away from 
the polar solvent environment, at a given pH. The introduction of this 
charge centre will attract counter ions and solvent through the 
aggregate structure and alter the distribution of the hydrophobic and 
hydrophilic sections of the molecule. It was reasoned, that the 
combination of these effects may cause the aggregate structure 
around the protonated molecule to be disrupted (Figure 12). Amine 
groups were considered the most appropriate functionality for the site 
of protonation. Amines are affected less by the polarity of their 
solvating environment than, for example, carboxylate I carboxylic acid 
functionalites. This is due to the effects of solvating the differently 
charged species and is shown by the equations and data in Figure 13. 
The equilibrium relating to amine protonation possesses no overall 
change in the number of charged species, whereas carboxylate 
protonation leads to charge neutralisation, which is accompanied by 
significant changes in the free energy of solvation 58 . 
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Ambient Physiological pH Lower Endosomal pH 
Figure 12. Schematic Diagram Showing The Possible Disruptive Action Of Additive 
Molecules With Mid-Chain Sites Of Protonation 
This low dependence on the polarity of its environment will also 
tend to reduce any pKa change undergone by an amine functionality 
on aggregation. In considering those pKa changes, the choice of 
ethanol is made here to model the reputed real micropolarity in the 
interior of a typical micelle. 
HAZ+l + SH + 
For Z = 0 pKa changes little with solvent polarity I dielectric constant 
e.g. NH 4 + /NH3 ~PKa (H2 0-Et0H) = -1.2 
For Z = -1 or -2 pKa is reduced significantly as solvent dielectric 
constant increases 
e.g CH3 COOH/CH3 COO - ~PKa (H 2 0 -EtOH) = -5.4 
Figure 13 Information Showing the Effects of Solvent Polarity on the pKa of Different 
Functionalities68. 
Prior work in Durham69 on molecules of this type involved the 
synthesis of long chain systems with an aniline group at the centre 
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(Figure 14). The p.Ka of these anilines in dilute solution was around 5, 
so on introduction to an endosome at ambient physiological pH, the 
molecules would be less than 1 % protonated and would become 
significantly protonated as the endosome aged and acidified. 
pK8 = 4.0 0.61 mM (0.1 M Me4NCI (90%MeOH/1 O%Water)) 
pK8 = 2.7 0.36mM + 10mol% CTMAB (0.1M Me4NCI (aq)) 
pK8 = 4.6 0.67mM (0.1M Me4NCI (aq)) 
pK8 = 4.9 0.07mM (0.1M Me4NCI (80%MeOH/20%Water)) 
pK8 = 3.2 0.85mM + 20mol% CTMAB (0.1 M Me4NCI (aq)) 
pK8 = 3.1 0.085mM + 2mol% CTMAB (0.1 M Me4NCI (aq)) 
Figure 14 pKa Values determined for aniline systems in free solution and when eo-
aggregated with CTAB69 · 
However, as mentioned in chapter 1, aggregation perturbs the free 
energy changes that characterise the protonation of a species, with 
respect to those in dilute homogeneous solution. Despite the choice of 
the amine functionality, the p.Ka of the aniline systems produced was 
found to be suppressed significantly on aggregation (Figure 14). As a 
result of this suppression, the p.Ka of the anilines was reduced below 
the pH 5 to 6 range required to be active as an endosome release 
trigger. In order to overcome this problem, it was decided to 
investigate species possessing a p.Ka value in dilute solution of 
between 8 and 9. The molecule chosen to fulfil this role was a 2,5 
disubstituted pyridine with a methylamine substituent at the 2 
position. The effect of having the amine functionality in close 
proximity to the pyridine ring and the heteroatom, shifts the p.Ka of the 
amine up towards the desired range. This is revealed by examining 
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literature data for the protonation of simple pyridine-2-methylamines 
(Figure 15)7°. The choice of the 2,5 substitution arrangement was to 
maintain as straight a chain as possible, in order to promote self- and 
eo-aggregation. 
~NH, 
pKa = 8.61 pKa = 9.01 
Figwre 15 pKa Values found for simple pyridine-2-methylamines (298 K I= O.lM 
NaC1)10 
2.2 Synthetic Route To 2,5~Difunctiona1lised Pyridine 
Systems 
R 
R = Alkyl Chain 
(f) 
X=NMe 3 
Figure 16 General structure of pyridine based mid-chain protonation species 
Initial routes to the general target 2,5-pyridine (Figure 16) were 
based around modifications of commercially available 2,5-pyridine 
precursors such as 2,5 lutidine and pyridine-2,5-dicarboxylic acid. In 
each case, routes designed using these pyridine starting materials 
encountered significant problems with regard to yield, versatility or 
selectivity of reaction before the desired product could be synthesised. 
The first proposed route from 2,5 lutidine shown in Figure 18 
encountered problems with the modification of the methyl group at 
the 5-position. Selective functionalisation of the 5-methyl group, for 
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example, was attempted by performing radical bromination on the 
intermediate amide. With limited availability of the amide 
intermediate, a readily available model compound 2-bromo-5-methyl 
pyridine was chosen to be used in attempts to optimise the 
bromination conditions. This compound could be used to synthesize 
compound [ 2 ] via the formation and subsequent hydrolysis of 2-
cyano-5-methyl pyridine [ 1 ] (Figure 17). 
Br 
Cu(I)CN, Et4N+ CN-
)1111 
Pd2 (dba)3 , DPPF 
1,4 Dioxane CN 
[ 1 I 
Figure 17 Formation of 2-cyano-5-methylpyridine [ 1 ] via Pd catalysed cyanation 
The radical brominations were carried out in carbon tetrachloride 
using N-bromosuccinimide to generate the succinimidyl radical and 
with AIBN as a radical initiator. The bromination reaction when 
carried out on the model compound, 2-bromo-5-methyl pyridine gave 
rise to mono- di- and tri-bromo products, which could be separated 
from each other and the remaining starting material using flash 
column chromatography. Yields of the more useful mono and di-
bromo products were 20% and 25% respectively. However, when 
bromination of the amide intermediates ([ 3 ] and [ 4 ]) was attempted 
there was no observable reaction. This was thought to be due to the 
effect of the long alkyl chain interfering with the approach of the 
reacting radical and inhibiting reaction. 
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[ 2 J OH 
[ 5] R=C8H 17 
[ 6] R=C6H 13 
0 
NHR 
Figure 18 Initial steps in proposed synthetic route from 2,5-lutidine 
Routes based around the dicarboxylic acid starting material 
(Figure 19) used some steps common to the lutidine route, but 
encountered problems in the reduction of the amide group formed 
from the coupling reaction. The 5-ester-2-amides, [ 8 ] and [ 9 ], were 
reduced using borane THF complex. However, analysis of the mixed 
products from the reaction by 1 H NMR and IR, showed evidence that 
as well as amide reduction, both the ester and the pyridine ring had 
undergone reduction. It is thought possible that the pyridine is 
activated to this borane reduction by the proximity of the ester 
functionality to the ring. Searches of appropriate literature sources, 
including Beilstein, Web of Science and SciFinder, failed to identify 
any previous observations to support this hypothesis. 
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OH 
l 7 I 
Problems encountered with 
amide reduction leading to 
reduction of pyridine ring 
with borane or low 
reactivity with milder 
reducing agents 
Figure 19 Initial steps in synthetic route from pyridine 2,5-dicarbox:ylic acid 
In each of the above cases the routes were abandoned as work on 
other routes began to show greater promise of success. The route 
eventually successful, is less commonly used than the routes based 
on the modification of substituted pyridines. It relies upon the 
formation of a 6-membered ring via a [4+2] cycloaddition strategy. 
The key stage involves an aza-Diels-Alder reaction which was used to 
form a 2, 5 disubstituted pyridine 71 . Following the application of this 
pyridine ring forming reaction, the steps found to be effective during 
earlier synthetic routes attempted were used to complete the synthesis 
of the desired cationic amphiphile. By using n-alkyl aldehydes of 
different length to carry out the reactions shown in Figure 20, it is 
possible to vary the alkyl chain length at the 5-position in the final 
pyridine. 
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Figure 20 Formation of the aza-diene used in pyridine ring synthesis71.125-127. 
Two molecules were synthesised for this work, one beginning with 
dodecanal to give a decyl chain at the pyridine 5-position [ 11 ]and the 
other starting from octanal leading to a shorter hexyl chain [ 10 ] . The 
aza-Diels-Alder reaction of the hydrazone products [ 12] and [ 13] 
from Figure 20 with chloroacrylonitrile gives rise to 5-alkyl-2-
cyanopyridines [ 14] and [ 15] in good yield. 
Hydrolysis of [ 14] and [ 15]. using potassium hydroxide in 
ethanol, gives rise to the 2-carboxylic acid compounds [ 16 ] and [ 1 7 
] . However, an early synthesis in which the hydrolysis was given 
insufficient reaction time, yielded the intermediate 5-hexylpyridine-2-
carboxamide [ 22 ] . This product formed crystals of suitable quality to 
allow single crystal X-ray diffraction to be performed. The resulting 
structure is shown in Figure 22 and 23, with further details included 
in Appendix 1. 
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C10H21 
R 
OH 
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R 
NHR' 
0 
[ 16] R = C5H13 [ 18] R = C6H 13 
[ 17 ] R= C 10H21 
R 
H 
N 
Borane: THF 
OH 
[ 19 ] R= C 10H21 
[ 20 ] R = C6H 13 
[ 21 ] R= C10H 21 
Figure 21 Reaction Scheme Showing Aza-Diels-Alder Pyridine Formation and the 
Amide Coupling Step (as in Figure 20, R = C5H13 or CwH21.)7l.l 27 
The alkyl chain, adopts the expected extended linear 
conformation and it can be seen in the packing diagram (Figure 23 ) , 
that these chains align themselves into organised rows. The packing 
diagram also shows intermolecular hydrogen-bonds (dotted lines) 
between the amide carbonyl oxygen and the acidic pyridine C-6 
hydrogen. 
Having formed [ 16 ] and [ 1 7 ] , following complete hydrolysis of 
the [ 14] and [ 15], it was possible to make use of the amide coupling 
route used in previous syntheses (Figure 18 & Figure 19) to afford the 
desired aminomethyl compounds (Figure 21). 
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[ 22 J 
Figure 22 Crystal structure of 5-hexylpyridine-2-carboxamide [ 22) (for more 
detailed information see Appendix 1) 
Figure 23 Crystal packing of 5-hexylpyridine-2-carboxamide (for more detailed 
information see Appendix 1). 
To avoid complications in the early steps of the synthesis, it was 
decided to locate the head group on the 2-position substituent. 
Variations are possible in the length of the amine alkyl chain by 
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coupling with different n-alkyl amines. However, readily available 6-
aminohexan-1-ol was used here first, as it gave a simple route to the 
inclusion of a charged head group (Figure 24). After BOC protection of 
the amine functionality, the alcohol compounds [ 23] and [ 24) were 
converted to the reactive mesylate compounds [ 25 ] and [ 26 ] . With 
its improved properties as a leaving group, the mesyl compounds were 
then treated with a solution of trimethylamine in ethanol to produce 
the cationic trimethylammonium compounds [ 27] and [ 28] with a 
methanesulphonate counter ion. The BOC protecting group was then 
removed in the conventional manner using TFA. At the end of this 
step, a counter ion system predominatly comprised of trtflate, with the 
possibility of some remaining mesylate, was present. Using DOWEX® 
1X8 (Cl) strong anion exchange resin, this mixed anion system was 
replaced to leave chloride as the sole counter ion. These chloride salts 
[ 29 ] and [ 30 ] were then characterised by NMR and accurate 
electrospray mass spectroscopy. Figure 25 shows the accurate ESMS 
spectra for the two pyridine surfactant compounds. The sodium iodide 
reference (m/z 172.884) can be clearly seen as a truncated peak in the 
spectrum for the hexyl compound (m/z 334.3191), as can a peak 
corresponding to the doubly charged species (m/z 167). 
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Figure 25 Accurate electrospray mass spectra for compounds [ 29 ](m/z 
334.3191) and [ 30 )(m/z 390.3847). 
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2.3 Aggregation and Protonation Properties 
In addition to the spectroscopic characterisation of the two target 
molecules produced, N,N,N-trimethyl-2-{[(5-hexylpyridin-2-
yl)methyl]amino}hexan-1-aminium chloride [ 29] and N,N,N-trimethyl-
2-{[(5-decylpyridin-2-yl)methyl]amino}hexan-1-aminium chloride [ 30 ] , 
their CMC and pKa values were determined. These values were then 
considered in the design of further experiments to assess their ability 
to cause aggregate disruption. 
2.3.1 CMC Determination 
[ 29] 
~ 
N 
[ 30] 
e 
Cl 
The critical micelle concentration for each of these compounds 
was measured using two methods. Firstly, conductivity measurements 
were undertaken as a function of concentration and secondly the CMC 
was determined using pyrene as a fluorescent polarity probe. Each of 
these methods has been used frequently to measure CMC and should 
give rise to similar values47.48.76. 
As was mentioned in Chapter 1 (section 1.3.1). the CMC can be 
observed and measured by the change in the conductivity of a 
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solution. This is done by preparing solutions, of the surfactant 
molecule being analysed, in increasing concentration using high 
purity water (:5 0.045 pScm-1) to minimise background conductivity. 
The conductivity measurements were made using a Jenway 4010 
conductivity meter and a pair of clean platinum electrodes positioned 
1cm apart. The solutions of [ 29] and [ 30] were prepared using 
ELGA Ultra High Purity water; the initial pH of the solutions prepared 
was between 4 and 5. The addition of base needed to adjust these 
solutions to the required pH 7 .2, increased the electrolyte content of 
the solution to such an extent as to mask the relatively small change 
in conductivity due to micellisation. 
a) Pyrene Fluorescence Method for CMC Determination 
Pyrene can be used as a fluorescent probe for CMC determination 
as the spectral form of the emission from the excited rr-system varies 
depending on the micropolarity of its surroundings.72.73.74 Combined 
with the fact that the planar organic pyrene molecules readily 
associate with the hydrophobic sections of surfactants as they 
aggregate in aqueous solution, this leads to the observed emission 
spectrum from pyrene in solution with surfactants below their CMC 
being different to that of pyrene in solution with surfactants at or 
above their CMC. Solutions of the pyridine surfactant to be measured 
were prepared over a range of concentrations, from 0.025mM to 
2.5mM. The samples for measurement were prepared by taking 
2.95ml portions of the aqueous surfactant and adding 50pl of pyrene 
solution in methanol (0.125mM). This gives rise to a pyrene 
concentration of 2 x 1 Q-3mM in the samples used for the fluorescence 
measurements. The small quantity of methanol should have little 
effect on the overall micropolarity of the aqueous solution or the 
aggregation properties of the surfactant. This assumption has been 
made in several earlier analyses using this approach75,76,77. The CMC 
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is evaluated from a plot of the ratio of two maxima of the pyrene 
emission spectra against concentration of 75-77 surfactant. The pyrene 
emission spectrum shows five local maxima across its emission range, 
the fourth (AMAX - 386-388nm) is usually only seen as a shoulder peak 
on the fifth (AMAX -392-393nm) and may in many cases be difficult to 
disc em (Figure 26). The relationship between several of these maxima 
changes with the micropolar environment. The I1 :I3 ratio and the lJ :Is 
ratio have both been used to determine CMC78. However, more recent 
investigations have shown CMC values determined using the I1 :Is ratio 
match more closely with values determined using other methods 77. 
This ratio was therefore used in this work. 
Pyrene Emission Spectrum 
360 365 370 375 380 385 390 395 400 
Wavelength (nm) 
Figure 26 Typical aqueous pyrene emission spectrum showing five local maxima. 
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b) CMC Measurements for Pyrldine Species 
The pyrene emission ratio data was used to calculate the CMC 
values shown in Table 1. (The experimental data can be found in 
appendix 2) 
Species 
[ 29) 
I 30 I 
CMC Value determined at pH 7 
1.45mM 
0.52mM 
Table 1 CMC values for [ 29 I and [ 30 I determined via pyrene fluorescence. 
Figure 27 shows the plot obtained from a CMC determination 
experiment for species [ 30 1 using pyrene fluorescence. The CMC is 
defined as the concentration of surfactant at which any further 
reduction in concentration would lower the micelle population to zero. 
The CMC is usually determined from data plots as the first 'break' 
point, or where two sections of linear change within the data plot 
meet. Having determined CMC values for both [ 29 ] and [ 30 1 it was 
then possible to prepare an experiment to measure the pKa of [ 29 ] 
and [ 30 1 in dilute solution and also to include them below their CMC 
in a eo-aggregate with a well know cationic surfactant. The cationic 
surfactant chosen was CTAB79.80 (CMC 0.85-0.92mM77.8l). 
Experiments were carried out using mixtures of CTAB and [ 29 ] or [ 
30 1 to assess the extent of pKa suppression with aggregation. 
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a 
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Figure 27 Pyrene method for erne determination with [ 30 [ (pH 7 295K) 
2.3.2 Measurement of pKa 
The pKa of the pyridine species was measured by monitoring the 
change in UV absorbance as a function of pH. The proximity of the 
secondary amine group to the pyridine was expected to lead to a 
change in the polarisation of the C-C a-bond in the 2 position, and 
hence the absorbance behaviour of the pyridine ring. following 
protonation of the amine. A more direct effect was also expected, at a 
point where the pyridine nitrogen itself was protonated. Initial 
experiments were performed to assess the possibility of using 
fluorescence emission as well as absorption spectroscopy. However. 
there was insufficient observable change in the pyridine emission 
spectrum with pH to use this method. The UV absorbance maximum 
was seen to shift from 264nm to 276nm in certain cases. as the pH 
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changed from 5 to 12. This change was used to assess the pKa of the 
pyridine species both in free solution and as part of a mixed aggregate 
with CTAB. Solutions of both [ 29 1 and [ 30 1 (0.04mM, 22°C) were 
prepared as were solutions containing CTAB(l.2mM, 22°C) and -1 
mole percent [ 29] or [ 30] (0.013mM, 22°C) and solutions containing 
CTAB(l.2mM, 22°C) and -5 mole percent [ 29 ] or [ 30] (0.062mM, 
22°C ). All solutions were prepared using Purite water (0.05 Sem-I) and 
a duplicate set of solutions were prepared with 0.1M NaCl solution. In 
each case, the solution pH was varied from 3-12 using 0.1M aqueous 
solutions of NaOH or HCl: the pH was measured using a glass 
electrode and a Jenway 3320 pH meter calibrated (±0.02) using 
standard pH 4, 7 and 10 buffer solutions. UV absorption spectra were 
measured at intervals across the entire pH range using a UNICAM 
UV2 spectrometer (bandwidth 0.25nm). Figure 29 shows the raw data 
obtained for [ 30 ] in dilute solution and for the same compound as a 
5 mole percent eo-aggregate with CTAB. The change in maximum 
absorbance seen at low pH in each of the plots in Figure 29 is most 
likely to be due to the protonation of the pyridine nitrogen (Figure 28) 
and was a common feature in each of the experiments undertaken 
pH>9 
Figure 28 Protonation scheme for aminoalkylpyridines 
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Figure 29 Data plots showing maximum absorbance change vs pH, For [ 30 ] In 
solution and in 5 Mol% ratio with CTAB. 
Optimum curves were fitted to the selected sections of the 
experimental data by using CurveExpert v.l.37 curve fitting 
12 
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software82 and the resulting best fit equations used in the calculation 
of the pKa values. 
The pKa values obtained for both compounds in dilute solution 
and as eo-aggregates are shown in Table 2. The solutions containing 
0.1M NaCl showed no observable difference in behaviour to those 
without the constant ionic background and so the data were 
combined. From these results the suppression of pKa on aggregation 
can be seen. The greatest effect being observed in the longer chain 
product [ 30 ] at 5 mole percent, while compound [ 29 ] shows much 
smaller shifts in pKa when included at the 1 and 5 mole percent levels 
used in this experiment. 
Am:2hiRhUe Concn (mM) CTAB Concn (mM) ~Ka (:1: 0.25) 
[ 29] 0.04 none 
[ 30] 0.04 none 
[ 29] ; 0.013 1.2mM 
[ 30] ; 0.013 1.2mM 
[ 29] ; 0.062 1.2mM 
[ 30] ; 0.062 1.2mM 
Table 2 pKa Values for pyridine species [ 29 ]& [ 30]. measured using UV-
spectroscopy (lcm cell path, 295K) 
9.4 
9.3 
8.3 
7.6 
8.6 
7.4 
Both of these compounds show protonation constants close to 
those expected and close to those of similar compounds found in the 
literature (Figure 15). The highest suppression seen for compound [ 30 
] only reduces the pKa by 1. 9 units to 7.4 which is probably not 
sufficiently low for the proposed function. 
In order to reduce the pKa still further, either electron-withdrawing 
groups need to be introduced into the amine ~-position (e.g. a CF2 
n1oiety) or longer chains should be incorporated at C-5 and/or C-2, in 
order to encourage greater hydrophobic interactions with the eo-
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aggregate and therefore, further suppress the apparent pKa in the 
aggregated complex. 
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Chapter 3 
3 :EDTA./DTPA Diamide Based Twin Chalm Alnphiphile 
Systems 
3.1 Twin Chain System Approach 
Producing pH sensitive amphiphiles, with twin chain lipid-like 
structures, offers the potential for greater affinity with liposome and 
bilayer vesicles, along with a potentially enhanced level of disruption 
in these more rigid aggregate structures. The lipophilic EDTA/DTPA 
structures chosen also allow for the possibility of a response to the 
changing metal ion concentrations which are also found within the 
endosomal compartment. 
Each of these systems was designed so as to produce twin chain 
surfactant molecules with the amino portion of the molecules forming 
the hydrophilic head group and the two amide alkyl chains aligning to 
form the hydrophobic tail section of the amphiphile. Amphiphilic 
DTPA dialkylamides have previously been synthesised and their 
lanthanide complexes used in the NMR study of liposomes and 
'bicelles' (bilayer micelles.)83,84 . Both DTPA and EDTA have strong 
metal binding properties and so both the rates and the equilibria 
defining metal ion complexation and dissociation are intrinsically 
sensitive to ~[Mn+] as well as to changes in pH. Both EDTA and DTPA 
form dianhydrides and reaction with 2 equivalents of amine produces 
a diamide ligand forming charge neutral complexes with doubly and 
triply charged metal ions respectively. These diamides generally form 
metal complexes of lower thermodynamic stability and of reduced 
kinetic stability to acid catalysed dissociation. The sensitivity of EDTA 
and DTPA diamides, to pH changes within the pH 4 to pH 7 range 
required for response to endosomal acidification. is seen in the 
published pKa data for the various protonation events involved in 
EDTA and DTPA diamide solutions. For EDTA species the protonation 
steps of most interest are those of the two tertiary amine nitrogens of 
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the ethylenediamine structure, with pKa values of 3.5- 4.5 and 6.6-
7.3 respectively85. DTPA protonates in much the same way. The first 
site to protonate in this case is likely to be the central nitrogen in the 
structure, followed by the other tertiary amines. DTPA bisbutylamide 
has pKa values of 9.36, 4.44 and 3.31 for these dissociation stepsB6. 
D'fPA Diamide 
Hydrophilic 
Section 
EDTA Diamide 
0}--oH 
( H 0 N-e~ /'L v 
( 
N \""/n 
N-~Y~~ 
)-OH O 
0 
Twin Hydrophobic 
Chains 
Figure 30 General structures of EDTA and DTPA diamide molecules and diagram 
representing twin chain amphiphile structure 
The potential for the DTPA molecules to adopt a conformation 
where the amide groups align, was identified by an analysis of 
published X-ray structural data using the Cambridge Structural 
DatabaseB7,BB,B9,90,9l,92 . The yttrium dibenzyl amide complex shown as 
an example in Figure 31 has the amide groups aligned approximately 
parallel, with the oxygens of the two amide groups 3. 16 A apart and 
the amide nitrogens 6. 95 A apart. This solid state data is a strong 
indication that DTPA diamides will be able to adopt the required 
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conformation in solution, with the alkyl chains of the amide 
substituents forming the hydrophobic section of the amphiphile. 
EDTA diamide crystal structures exhibit a number of different 
conformations depending on the nature of the co-ordinating metal, the 
extent of any structural modifications of the ligands EDTA section and 
the nature of the substituent in the amide R group. However, no EDTA 
diamide structures were found to show cis-related amide groups or 
amide alignment in the solid phase. 
Figure 31 Images from X-ray structural data for Aqua-(N,N"-
bis(benzylcarbamoylmethyl)diethy lenetriamine-N. N'. N"-triacetato)-
yttrium trihydrate, showing amide group alignmentB7. 
The examples shown in Figure 32, Figure 33 and Figure 34 are 
representative of EDTA bisamide structures. The (+)-(N,N'-1,2-
ethanediyl-bis(N-(carboxymethyl)glycyl-L-methionine)ethyl esterato)-
copper(II) sesquihydrate structure (Figure 32)9 3, shows the amide 
groups are trans-related. In the aqua-(N,N'-ethylenebis(N-
carbamoylmethylglycinato))-copper(ii) dihydrate structure Figure 3394, 
the amide groups are also trans-related, although the ligand is five 
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co-ordinate, leaving an amide group unbound. Figure 34 shows (N,N'-
bis(acetato)-N,N'-bis(N"-uracil-5-ylacetamido)-1 ,2-ethylenediamine)-
aqua-zinc tetrahydrate95. In this structure, the amide groups are also 
in a trans arrangement. However, the co-ordination to the metal 
through each of the amide oxygens in this case, has the effect of 
drawing the amide substituents towards the same axis, although not 
aligning them parallel with each other. The lack of cis-EDTA diamide 
structures in the solid state however, does not rule out the possibility 
of these conformations being adopted in solution by a simple 
pseudorotation. Such cis-EDTA diamides are potentially more 
favourable configurations, in terms of producing amphiphile 
molecules, as they bring the alkyl chain carrying amide R substituents 
into closer proximity. 
Figure 32 Image from X-ray structural data for (N.N'-1 ,2-ethanediyl-bis(N-
(carboxymethyl)glycyl-L-methionine)ethyl esterato)-copper(II) sesquihydrate93 
.! 
·t 
Figure 33 Images from X-ray structural data for aqua-(N.N'-ethylenebis(N-
carbamoylmethylglycinato))-copper(II)94 
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Figure 34 Images from X-ray structural data for (N,N'-bis(acetato)-N,N'-bis(N"-
uracil-5-ylacetamido)-1, 2-ethylenediamine)-aqua -zinc tetrahydrate95 
The synthesis of both EDTA and DTPA diamide compounds (Figure 
30) was achieved in high yield in a single step reaction. The 
dianhydride of either EDTA or DTPA was recrystallised and combined 
with 2.25 molar equivalents of the desired amine in dry THF, diethyl 
ether, pyridine or DMF (Figure 35). The resultant diamide products 
were purified simply by washing the white solid with several portions 
of the appropriate organic solvent, in order to remove any remaining 
amine. 
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DTPA Dianhydride EDT A Dianhydride 
THF /E~O/Pyridine/DMF 
DTPA Diamide EDT A Diamide 
Figure 35 Reaction scheme showing the formation of DTPA and EDTA diamides. 
The products were then characterised using elemental analysis and 
1 H NMR. Elemental analysis often indicated the inclusion of water in 
the structure of the solids. This method was used to synthesise the 
DTPA and EDTA dinaphthyl substituted amides , [ 31 ] and [ 32 ] 
respectively, along with; EDTA dioctylamide [ 33 ], EDTA 
didodecylamide [ 34 ] and EDTA dihexadecylamide [ 35 ] . 
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[ 31] 
[ 32] 
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In addition to the ligands listed, Zn2+ complexes of the EDTA 
dialkylamides [ 33 ), [ 34 ] and [ 35 ] were synthesised by combining 
the ligand with 1. 1 equivalents of zinc acetate in Purite TM water at 
reflux for three hours. The resulting white solid which precipitated on 
cooling was filtered and washed with copious amounts of cold Purite TM 
water. Again, characterisation by 1 H NMR and elemental analysis 
allowed the differences between the ligand and complex to be observed 
(Figure 36) 
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Figure 36 IH NMR (CD30D 300MHz) spectra of a representative EDTA diamide 
ligand [ 33 I and the corresponding zinc complex. 
In the free ligand, the geminal CHzN methylene groups appear as 
singlets (A, B, D.), except for the CONHCH2 resonance which appears 
as a triplet through coupling to the adjacent CHz group. In the zinc 
complex, the NCH2CH2N protons resonate to lower frequency as a 
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major AA'BB' second order multiplet. The CH2-CO resonances (A and 
B) also are rendered distereotopic by metal ion complexation, with 
geminal coupling constant of -16Hz. 
3.2 Studies on the DTPA-Diamide System 
3.3.1 Structure and Conformation 
In addition to an examination of related solid state structural 
data, the conformation adopted by the DTPA diamide structures in 
solution was probed by examining the behaviour of a related 
dinaphthyl amide derivative. This structure allowed the proximity of 
the two amide groups to be detected via fluorescence, through the 
formation of an intramolecular excimer (excited dim er 
[Nap h ..... Naph.]*) between the proximate naphthyl groups. Excimers 
can be formed by most aromatic hydrocarbons. one molecule in an 
excited state and the other in the ground state. In this situation, the 
usual repulsion which would be experienced by two ground state 
molecules at close intemuclear distances is replaced by weak 
stabilisation, leading to the formation of a weak dimer96,97. Emission 
from this excited dim er, gives rise to two molecules in the ground state 
and in close proximity. The ground state aromatic molecules 
experience the expected mutual repulsion and move apart following 
emission, leading to an absence of vibrational structure in the 
emission from the excimer. Excimer emission is characterised not 
only by the lack of vibrational structure seen in the monomer 
emission spectrum (Figure 37)98 , but, also by a wavelength shift. The 
potential energy curve diagram (Figure 38) shows clearly that the 
emission from an excited dim er should be of lower energy (longer 
wavelength) than that from isolated excited state monomers. 
If the naphthyl groups in the DTPA compound synthesised are 
able to adopt a conformation where they are close and parallel, then 
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this excimer emission should be visible in the fluorescence emission 
spectrum for the compound. 
300 350 
Naphthalene Monomer 
Emission 
400 
Wavelength (nm) 
Naphthalene Excimer 
Emission 
450 
Figure 37. Example of naphthalene fluorescence emission spectrum showing 
monomer and excimer emission. (compound [ 32 ] 295K H20 pH 5) 
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69 
Excimer 
Potential 
Energy 
' 
Structureless excimer 
emission at longer wavelength 
• 
Excited momoner and ground state 
monomer at larger separation 
Chapter 3 
} Vib< 
of 
ational levels 
excited state 
monomer 
Monomer 
emission 
Monomer 
absorption 
rh of rational levels ground state monomer 
.... 
.. 
Intermolecular 
Separation 
Figure 38 Schematic representation of excimer emission in terms of potential energy 
curves. The lower curve represents the ground state molecule and the 
upper curve that of a molecule in the first excited state.99 
3.3.2 Solution Behaviour 
Solutions of the dinaphthyl DTPA [ 31 ] compound were prepared 
and used in fluorescence experiments to determine solution 
conformation by monitoring the presence of the naphthalene excimer. 
Initial experiments were performed at pH 7.2 (HEPES Buffer) over a 
range of concentrations in order to determine if any excimer emission 
observed was due to intra- or intermolecular interactions. The relative 
intensity of the excimer emission compared to the monomer emission 
was calculated and was seen to remain constant at around 5-7%, 
independent of ligand concentration, indicating that an intramolecular 
excimer was being formed and therefore that the amide groups were 
able to align in parallel. 
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Further experiments were performed using the dinaphthyl 
substituted amide compound [ 31 I to determine the effects of pH 
variation on the conformation of the molecule and therefore the degree 
of excimer emission. The data from these experiments showed that the 
relative excimer intensity varied with pH to give a bell shaped profile. 
Excimer formation was at a maximum between pH 3.5 and 8 
remaining almost constant, while above and below these pH values its 
relative intensity fell sharply (Figure 39). This stable plateau of 
excimer intensity seems correspond to the pH range across which, the 
central amine of the DTPA moiety is protonated and one of the outer 
tertiary amines protonates (Figure 40). 
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Figure 39 Plot of relative excimer emission vs pH for DTPA dinaphthyl substituted 
amide species I 31 I 
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Figure 40 Diagram showing plausible protonation scheme for DTPA dinaphthyl 
substituted amide [ 31 ). 
The decrease in intensity at pH 3. 5 is most likely to be the 
consequence of electrostatic repulsion: as the third amine protonates 
the ion adopts a more extended conformation and the amide groups 
move apart. All these observations assume that the pKa values for 
species [ 31 ] are similar to those of simpler DTPA bisamides. 
Similar experiments were also carried out with a range of metal 
ions in solution, in a 1: 1 molar ratio, to determine the effect metal 
binding would have on the solution conformation and how it would 
modify the response of the molecule and excimer emission to pH. The 
metals chosen were calcium, lanthanum, yttrium and zinc. Calcium 
and zinc are know to be present in biological media, the calcium 
concentration, in particular is known to vary greatly between the 
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extracellular background (ea 1-2mM) and intracellular fluids (sub 
micromolar) . 
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Figure 41 Plot of relative excimer intensi ty vs pH for the DTPA dinaphthyl 
substituted amide [ 31 I showing response with metal ions in solution 
9 
The yttrium and lanthanum complexes form 9-co-ordinate structures 
with one water molecule and each of the ligand h eteroatoms bound in 
a tricapped trigonal prismatic structure87 . These metals were 
included to allow comparison of a wider range of co-ordination 
geometries. The inclusion of these metals in solution had little impact 
on the relative excimer intensity plots with the same features being 
present over the pH range from 2 to 8 (Figure 41). With each of the 
metal ions, the decrease in intensity from pH 8 to pH 11. observed in 
the free ligand was not seen. In the case of zinc, th e precipitation of 
zinc hydroxide from the solution prevented useful measurements 
being taken above pH 8.5. It would appear from this experimental 
data that the stability of DTPA bisamides in binding these metal ions, 
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removes any response to pH above pH 4. That is, the 1: 1 metal 
complex resists any protonation above pH 4, which is associated with 
a change in complex conformation. The response observed below pH 4 
is consistent with that of the free ligand and is most likely caused by 
the decomplexation of the metal, leaving the ligand free in solution 
and able to protonate. This stability of the metal complexes of [ 31 1 
reduces the suitability of these compounds for use in endosome 
triggered disruption systems. Complexation removes any response to 
the pH drop within the endosomal compartment, between pH 7. 2 and 
pH 4. The observation that the complexed DTPA ligand [ 31 1 appears 
to favour a conformation in which the amide groups can align, which 
can be seen from the relative excimer intensity (Figure 39, Figure 40, 
Figure 41). is consistent with the solid state data. The DTPA 
dinaphthyl substituted amide [ 31 1 excimer experiments showed no 
response to either pH or metal ion concentration within the range 
required for action as an endosomal release trigger. It is possible that 
related amphiphillic DTPA diamidesB3.84 may have the pKa values of 
the key protonation steps suppressed when included as part of an 
aggregate. However, the location of the tertiary amine groups in the 
hydrophilic 'head' section of the molecule may significantly reduce any 
pKa suppression which aggregation might cause. 
3.3 Studies on the EDTA~Diamide Systems 
3.3.1 Solution Conformation and Behaviour 
In order to investigate the conformations adopted by EDTA 
diamide species in solution, the EDTA bisnaphthyl substituted amide [ 
32 1 was synthesised by the method described in section 3.1. 
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[ 32 1 
This compound was then used to perform experiments similar 
to those carried out with compound [ 31 1. Firstly, concentration-
dependent experiments were carried out at pH 7.2 to confirm that the 
excimer observed was associated with an intramolecular process. The 
ratio of excimer /monomer emission intensity remained constant at 
-12% (pH 7), over the concentration range 0.1M to 0.5~-LM, consistent 
with intramolecular excimer formation. Further experiments were 
then performed to determine the response of compound [ 32 1 to 
changes in pH. The naphthalene excimer was observed for compound 
[ 32 1 with a relative excimer /monomer intensity ratio of between 10% 
and 70%. This is a significantly higher degree of excimer formation 
within the EDTA species [ 32 1 than was seen for the DTPA system [ 31 
], notwithstanding the X-ray structural data discussed above. 
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Figure 42 Plot of relative excimer intensity vs pH for the EDTA bisnaphthyl 
substituted amide [ 32 I 
The results of the compound [ 32 ] pH variation experiments are 
depicted in Figure 42. Changes in excimer intensity are observed 
within the desired pH range for endosomal triggering, i.e. between 4 
and 7. The first change, an increase in relative excimer intensity, is 
seen between pH 3 and 5. A much bigger change, a decrease in the 
relative excimer emission, was observed between pH 5 and 7. 
12 
These changes appear to correspond to the protonation I 
deprotonation of the tertiary nitrogens in the EDTA structure. Similar 
EDTA diamide derivatives show pKa values for these steps of between 
3.5 and 4.5 for the first and between 6.6 and 7.3 for the second85. 
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Figure 43 Diagram showing likely N-protonation scheme for EDTA diamides 
This leads to the conclusion that, the singly protonated species 
allows conformations to be adopted with the amide groups oriented 
more closely and more readily than either the doubly charged or 
unprotonated forms (Figure 43). Experiments were carried out in the 
presence of ZnCh and CaCh at equal concentration to the EDTA 
dinaphthyl substituted amide species [ 32 I in solution. These showed 
no excimer intensity change within the pH ranges seen for the free 
ligand. (Figure 44) In the experiments carried out using ZnCh, the 
initial change in excimer intensity was observed at much lower pH, 
which is consistent with the strongly bound metal only being 
displaced by protons at higher concentration. The intensity ratio then 
remained at a constant level of -15% until precipitation of zinc 
hydroxide at higher pH prevented further useful measurements being 
taken. The experiments carried out CaCh however, showed a similar 
response to the free ligand. The excimer intensity changes were shifted 
to lower pH, with the first occurring at pH 3-3.5 and the second 
around pH 4. Given that there is not likely to be much 'free' zinc (11) 
inside cellular systems 100 , the observed behaviour with pH/Ca2+ 
variations offers some potential in the definition of the desired 
responsive system. In particular the significant changes around pH 4-
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6, modulated by changes in Ca2 + concentration, fall close to the 
desired range. 
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Figure 44 Plot of EDTA Dinaphthyl substituted amide [ 32 I relative eximer intensity 
vs pH showing the effect of Ca2+ ions in solution 
3.3.2 Straight Chain Amphiphilic EDTA Dialkyl Amides 
The EDTA dialkylamides, [ 33 1, [ 34 1 and [ 35 1 were 
synthesised and characterised as described above. Compound [ 35 1, 
which has previously been synthesised by the same method, was 
studied in metal ion transport through organic solvents 10l. The 
critical aggregation properties of each ligand were investigated along 
with any pH dependent effects they might have on the stability of eo-
aggregate assemblies of which they were a part (sections 4. 1 a) and 
4.2). 
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3.3.3 CAC Determination 
Crttical aggregation concentration determination for the Cs, C12 
and C16 diamide compounds [ 33], [ 34] and [ 35] was undertaken 
using the conductivity method. The conductivity of each solution was 
measured and the molar conductivity measured as a function of the 
concentration of surfactant at 295K. The absolute values of the 
conductivity recorded are of lesser importance than the observation of 
the change in conductivity. This is all that is required to give a value 
for the CAC. 
'B 35 
....... 
~ 
t' 30 ·~ 
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Figure 45 Variation of solution conductivity with concentration of [ 34 ] (295K), 
allowing determination of the critical aggregation concentration: the line 
shows the fit to the experimental datapoints. 
Buffered solutions (pH 7.2 HEPES) of each of the three ligand 
species were prepared over a range of concentrations from ~ 1 J.!M to 
400 J.!M, using the same low conductivity water used in the earlier 
conductivity measurements. The CAC values determined for the three 
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species are shown in Table 3. (Further experimental data can be found 
in appendix 2). These values are considerably lower than for the 
pyridine species indicating much lower concentration is required 
before the amphiphilic molecules reach a saturation point in solution 
and begin aggregating. (Figure 45). 
The concentration/ conductivity plots show further changes at 
higher concentration. These further critical aggregation events could 
be due to the changes in aggregate form (Figure 10). As the EDTA 
diamides are likely to adopt a twin chain amphiphile arrangement in 
solution, it is possible with this structural similarity to natural twin 
chain lipids, that these observed events are linked to the formation of 
bilayer structures. Again, the CAC values determined were utilised in 
the design of further experiments to determine eo-aggregate properties 
and aggregate disruption effects. 
EDTA Diamide CAC Value determined at pH 7 
[ 33 1 (Cs) 0.12 (mM) 
[ 34 ](C12) 0.068 (mM) 
[ 35 ](C15) 0.0083 (mM) 
Table 3 CAC Values from conductivity experiments with EDTA diamides 
Following the determination of the aggregation properties of 
[ 29 1. [ 30 1. [ 33 1. [ 34 1 and [ 35 1. each of these species was used to 
form eo-aggregate micellar and liposomal systems in order to assess 
their ability to disrupt aggregate assemblies as a function of solution 
pH and metal ion concentration. While the EDTA based species have 
well known and strong metal binding properties, the presence of the 
amine at the pyridine 2-position in compounds [ 29 1 and [ 30 1 raises 
the possibility that these compound might also show some ion-
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chelating behaviour which may affect their behaviour within a micelle 
or bilayer membrane. 
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4 Aggregate Disruption 
4.1 Micellar Models 
4.3.1 CTAB Micelle Disruption 
Cetyltrimethylammonium bromide (CTAB) is the archetypal 
cationic detergent, forming well-defined cationic micellar aggregates 
102,103,104,105,106 with a CMC of 0.85-0.92mM77 . To assess the 
disrupting effects of the trigger molecules on this model micellar 
system, the following experiments were carried out using CTAB as the 
major component in eo-aggregates of varying composition. eo-
aggregate solutions, containing 5 mole percent of the pyridine or 
EDTA amphiphiles, were prepared. In each case, the solutions were 
prepared with a concentration of CTAB of 1.2mM, significantly above 
its CMC. In preparation of the solutions, the concentration of the 
additive pyridine amphiphiles, [ 29 ] (CMC 1.45mM) and [ 30 ] (CMC 
0.52mM) was maintained at 0.06mM (5 mol%), significantly below the 
CMC of either compound. However, to produce CTAB eo-aggregate 
solutions, containing the EDTA based species at 5 mole percent, with 
CTAB above its CMC, the concentration of the longer chain EDTA 
diamides [ 34 ]and [ 35] required, was close to or above the CMC 
measured for these compounds (CMC [ 34 ] 0.065mM, CMC [ 35 ] 
0.016mM). This situation is unavoidable, due to the relatively large 
difference in the CTAB CMC of 0.8mM and EDTA diamide CMC values 
below 0. 08mM. 
The solutions were made using O.lM NaCl to maintain a constant 
ionic background during the pH variation. Small aliquots of O.lM 
NaOH and HCl aqueous solutions were used to vary the pH. The 
fluorescence of pyrene was again used as a probe signal to determine 
the presence of the different micropolar environments expected 
following the onset of micellisation. As micelles are dynamic species 
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in constant equilibrium with the bulk surfactant in solution, it was 
not clear at the outset if the experiments proposed would be able to 
detect any change due to the effects of pH on the trigger molecules in 
the eo-aggregate. Disruption of the aggregate by the trigger, would be 
relatively rapid if it occurred and the surfactant molecules released by 
this disruption, could readily form another micelle and reincorporate 
the pyrene molecules. This process could easily occur after the 
addition and measurement of solution pH and before the emission 
observation could be undertaken. The average pyrene emission being 
observed would therefore show little or no difference to that of the 
stable eo-aggregate. Pyrene emission would also remain unchanged if 
the protonation of trigger molecules simply caused them to leave the 
dynamic micelle structure, as their aggregation properties changed, 
without causing any disruption of the micelle. 
a) EDTA Diamide Experiments 
The pyrene fluorescence experiments for the eo-aggregates of the 
EDTA diamides [ 33 I and [ 34 I, showed no significant change in the 
[]I Is emission ratio as a function of pH. Compound [ 35 I however, 
showed a clear change between pH 4.5 and pH 7.5 which can be seen 
in Figure 46. This change corresponds quite well to the changes seen 
in the pH variation of naphthyl excimer emission (section 3.3.1). 
However, due to the fact that this EDTA diamide species is above its 
self-aggregation concentration, it is possible that the effect on the 
pyrene emission ratio is, at least in part, caused by the pH dependent 
disruption of the self-aggregate of compound [ 35 ], with little effect 
being related to the CTAB eo-micelle system. It is difficult to be certain 
whether this is the case, without further experimental substantiation. 
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Pyrene Emission Ratio I 1/15 vs pH 
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Figure 46 Variation of pyrene I1 I Is ratio vs pH for EDTA dialkyl amides [ 33 I. [ 34 ] 
and [ 35] 
b) Pyridine Experiments 
The pyridine experiments were carried out, as discussed above, 
and the pyrene !1 I Is emission for the CTAB pyridine eo-aggregates 
remained virtually constant across the entire pH range observed. The 
data and results were very similar to those obtained for the shorter 
EDTA diamides. 
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In addition to the micelle experiments, the EDTA and pyridine 
based surfactant products were used as additives in liposome 
preparations. Liposome aggregates are bilayer structures which 
wholly enclose a volume of solvent and are considerably more stable 
than micellar systems. Amphiphiles, which form liposomes, are 
usually insoluble in aqueous solution, or at least not truly soluble in 
the traditional sense. They disperse only by forming bilayer aggregates 
and in this way they differ from micelle-forming amphiphiles. There is 
no solvated amphiphile population in solution and therefore no 
equilibrium exchange between the aggregate and this solvated 
population. Liposomes are similar in their gross structural features to 
biological cell membranes and are frequently made using the same 
amphiphilic components, in order to model the cell membrane. 
Liposome membranes, like cell membranes, allow some small 
molecules and ions to diffuse across the bilayer, however larger 
molecules cannot cross the membrane. The lipid used for the 
experiments carried out, was dimyristoylphosphatidylcholine (DMPC). 
This is a well known lipid molecule that forms stable unilamellar 
vesicles and has well characterised gel and liquid crystal phases 
(Figure 4 7). Unilamellar vesicles are those which have a single bilayer 
membrane enclosing the contents, in much the same way as a 
biological cell. Multilamellar vesicles can be thought of as having an 
"onion skin" structure of nested bilayers. These structures can be 
formed by simple solutions of lipid molecules but, in many cases 
treatment with ultrasound or extrusion of the initial solution through 
a membrane of a fixed pore size, will disperse these larger 
multilamellar systems in favour of the desired single membrane 
structures49. Liposomes can be eo-aggregate structures in the same 
way as micelles, they can also incorporate organic molecules 
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'dissolved' within the bilayer, or large molecules such as proteins 
which bridge the membrane. 
Figure 47 SEM image, of a cryogenically frozen DMPC unilamellar liposome 
dispersion showing a range of vesicle sizes 107 
4.3.1 Fluorescence Probes For Liposomal Membrane Disruption 
In order to detect any disruption caused by the inclusion of the 
trigger molecules, fluorescence assays used to detect liposome 
leakage, bursting or membrane pore formation were employed. The 
most common of these assays employs carboxyfluorescein (CF); CF is 
a fluorescent probe, which undergoes self-quenching above a critical 
concentration. By forming liposomes containing CF above this critical 
concentration, removing the liposomes from the CF solution in which 
they formed and then collecting emission spectra, it is possible to 
detect any leakage from the liposomes by monitoring the emission 
wavelength of dilute (unquenched) CF. 108 However, carboxyfluorescein 
fluorescence is affected significantly by pH. Indeed, it has been used 
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to monitor pH within cell environments109. The use of this analysis 
method, for detecting liposome leakage is therefore only useful over a 
very narrow pH range, around pH 7. The altemative assay chosen, 
involves a quencher pair 8-aminonaphthalene-1 ,3,6-trisulfonic acid 
(ANTS) and p-xylene-bis-pyridinium bromide (DPX). This system 
works in a similar way to the CF system, using liposomes containing 
both components. The DPX quenches the ANTS fluorescence and so, 
intact liposomes show no emission. On liposome disruption, both 
ANTS and DPX are released into the extemal solution environment. 
The relative concentrations of ANTS and DPX change and the ANTS 
fluorescence is no longer quenched. By observing the change in ANTS 
fluorescence intensity, the level of liposome disruption can be 
determined (Figure 48)110,1 11 . This quencher pair method has been 
shown to be effective over the whole of the desired pH range for the 
experiments, from pH 7.5 to 4.5111. 
I 
·w Llp s om~ Rel~ase 
50 I 
DPX 
Qu er 
Figure 48 Diagram representing the detection of liposome disruption, using 
ANTS/DPX112 
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4.3.2 Liposome Preparations and Disruption Experiments 
Liposomes were prepared, using known quantities of pure 
synthetic DMPC and the required trigger amphiphile, at 5 mole 
percent concentration. The mixed amphiphiles were coated onto the 
surface of a flask from solution in chloroform and dried under high 
vacuum. A solution, containing ANTS ( 12 mM) and DPX (45mM) 
HEPES buffer (5mM) and KCl (20mM), was added and the amphiphile 
mixture dissolved with agitation. The resulting very pale, opaque lipid 
solution (pH 7.5), was then subjected to a series of freeze/thaw steps 
before being extruded 3 times through a 1 OOnm polycarbonate 
membrane. After these extrusions, the more transparent resulting 
solution, was passed down a Sephadex™ PD-10 column, using a 
solution of Hepes (5mM) and KCl (100 mM) as eluent. Small (50p.l) 
samples of the resulting clear, slightly blue, liposome solution, were 
diluted into one of the pH buffered solutions listed in Table 4. All 
solutions were prepared, such that the osmotic potential across the 
liposome membrane was as low as possible, to prevent liposome 
bursting. 
Buffer & Concentration KCI Concentration Solution pH 
HE PES (5mM) 1 OOmM 7.2 
MES (5mM) 100mM 6.1 
Acetate (5mM) 100mM 4.8 
Table 4. experimental buffer solution details for ANTS/DPX liposome disruption 
experiments. 
Experiments monitoring the intensity of ANTS fluorescence were 
carried out using the above solutions at 295K. The ANTS fluorescence 
intensity of each solution was measured (Ii), firstly, before a small 
amount ofTriton-X100, a non-ionic surfactant, was added (0.25ml 10 
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wt% (aq)) and subsequently, following addition and agitation (Itrt). The 
non-ionic surfactant has the effect of completely disrupting the 
cationic liposomes in solution. The ANTS fluorescence emission 
intensity of the measurements, taken after the addition of Triton, litri, 
were considered to represent the emission from 100 percent 
'dequenched' ANTS, as all the liposomes containing the quenched 
system are believed to be disrupted under these conditions. The 
values of It and IItri were used to calculate the percentage difference ~% 
between the fluorescence, before and after addition. 
~o/o = 100- 1°/o 1°/o=X x1oo 
ri 
ltri = 1 00°/o dequenched emission 
Figure 49 Equations used to calculate t.% values shown in Table 5 and Table 6 
By comparing the results for the additive-containing liposomes, 
with values for a control of pure DMPC, a comparison of the effect of 
each additive on liposome stability as a function of pH, could be made. 
The initial experiments, with additive levels of 5 mole percent showed 
little variation across the three pH values (Table 5). Solutions of 
liposomes were then prepared, with the additive levels set at 25 mole 
percent. 
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Additive (5mol0/o) pH ANTS Emission Change(~%) 
(± 6°/o) 
None 7.2 10% 
None 6.1 12% 
None 4.8 12% 
[ 351 7.2 24% 
[ 351 6.1 27% 
[ 351 4.8 26% 
[ 301 7.2 14% 
[ 301 6.1 14% 
[ 301 4.8 14% 
Table 5 Showing percentage ANTS emission intensity change, on addition of non-
ionic surfactant, to solutions of different liposomes at pH 7.2, 6.2, 4.8 at 
295K 
With the additive levels at 25 mole percent, the effects on the 
membranes with pH became more apparent. The shorter chain, Cs 
and C 12, EDTA derived surfactant molecules [ 33 1 and [ 34 1 along 
with, the C6 pyridine molecule [ 29 1, still gave rise to little observable 
change. However, both the hexadecyl EDTA diamide [ 35 1 and the 
pyridine species with the decyl chain, [ 30 1, showed a significant effect 
on the membrane. With the additive levels at 25 percent, experimental 
measurements were also taken at 308K so as to reflect more closely 
an in vivo temperature. 
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Additive pH Temp. ANTS Emission Change 
(K) (A0/o) (± 6°/o) 
None 7.2 308 12% 
None 6.1 308 12% 
None 4.8 308 12% 
[ 35 ](25%) 7.2 295 44% 
[ 35 1 (25%) 6.1 295 40% 
[ 351(25%) 4.8 295 31% 
[ 30 1 (25%) 7.2 295 -4% 
[ 30 1 (25%) 6.1 295 -6% 
[ 30 1 (25%) 4.8 295 -3% 
[ 35 1 (25%) 7.2 308 12% 
[ 351 (25%) 6.1 308 12% 
[ 35 1 (25%) 4.8 308 8% 
[ 30 1 (25%) 7.2 308 21% 
[ 30 1 (25%) 6.1 308 5% 
[ 30 1 (25%) 4.8 308 6% 
Table 6. Showing percentage ANTS emission intensity change, on addition of non-
ionic surfactant, to solutions of different liposomes at different temperature 
and percentage composition. 
DMPC is known to have a gel to liquid crystal thermal transition at 
297Kll3, so the action of raising the temperature crosses this 
transition, allowing such effects attributed to the different bilayer 
phase to be observed (Table 6). 
Changes with pH were evident for liposomes prepared with the CtG 
EDTA diamide (25% at 295K). It can be seen from the data that the 
EDTA based systems appear to have an initially stabilising effect on 
the liposomes at pH 7.2, as the percentage change observed on Triton 
addition, is much greater than for the pure DMPC liposomes. Long 
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chain DTPA diamide compounds have been used previously to align 
lipid membranes in NMR experiments. The EDTA diamides 
synthesised here could presumably have similar effects on liposomes. 
which could account for more stable liposomes being formed by the 
EDTA/DMPC mixed membranes. The pyridine species [ 30 1 however, 
showed no pH dependent disruption. When the percentage change 
values for this species are compared with those for the pure DMPC, it 
can be seen that the presence of the pyridine species is having a 
destabilising effect on the liposome membrane. at each of the pH 
points used in the experiments at 295K. At the higher temperature, 
the stabilising effect of the EDTA compound [ 35 1 is less apparent, the 
more dynamic lipid leading to greater overall freedom of movement. At 
308K, the pyridine species [ 30 ]is seen to cause disruption, this 
time related to the solution pH. It is possible that the more dynamic 
lipid phase, is able to form more stable eo-aggregates with the pyridine 
species at pH 7 and above, with the protonation of the additive 
causing the desired destabilisation of this eo- aggretate at the lower 
pH points examined. 
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5 Conclusions and Future Work 
The experimental work, carried out and described in chapters 2, 3 
and 4 has given rise to 5 amphiphile species, which respond to 
changes in pH, and some ([ 33 ]. [ 34 ] and [ 35 ]) which respond, to a 
lesser degree, to changes in [M2+]. Their efficacy as aggregate 
disruption species appears, from the analytical results obtained, to be 
rather limited. The EDTA diamide species [ 35] has been shown to 
possess pH induced disruption effects, when included at 25 mole 
percent in a DMPC liposome membrane model, using the ANTS/DPX 
membrane leakage assay. However, this level of inclusion is at the 
upper limit of that which is desirable. The pyridine species were 
eventually synthesised cleanly using a versatile and effective route. 
The pyridine-amine targets were specifically chosen to have p.Ka values 
above the desired range for endosomal triggering, of between 4.5 and 
7. in order that on the suppression of p.Ka. previously observed with 
aggregation, the pyridine amine p.Ka would be suppressed into the 
desired range. However, even after suppression within a CTAB 
micellar eo-aggregate, the measured p.Ka was still above the desired 
range. The pyridine species [ 30]. on inclusion in a simple DMPC 
liposome model, showed some pH dependant response at levels of 25 
mole percent at 35°C, above a critical phase transition for the lipid 
model used. However, due to the quantities of lipid available and the 
time constraints placed on this work, by both funding and liposome 
lifetimes, only a small number of experiments were carried out at this 
elevated temperature. The other species of shorter length appeared to 
have much less, or no, observable impact on aggregates in which they 
were included. 
In order to confirm the effects observed for compounds [ 30 ] and 
[ 35 ] , further liposome experiments are needed. In addition to the 
collection of more data points, other lipid molecules or mixtures of 
lipids, could be used in the formation of liposomes for future 
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experiments. The effects of the inclusion of cholesterol and other 
molecules into the membrane could also be investigated. 
In terms of producing other, potentially more effective, pH 
sensitive disruption species to undergo similar testing, an altemative 
strategy to mid-chain sites of protonation might be a tail terminus site 
as this type of system has been investigated and found to be effective 
with photo-triggered systems. This possibility could be investigated 
with a modification of the route to the N-[(5-methylpyridin-2-
yl)methyll-N -alkylamine molecules synthesised in this work. The 
flexibility of the pyridine synthesis used to form [ 29 I and [ 30 I, also 
allows the possibility of including the electron-withdrawing 
substituents mentioned earlier, ~-to the amine group (Figure 50). 
This could be achieved by a using a modified amine in the coupling 
step. 
R 
R = Alkyl Chain 
(±) 
X= NMe3 
Figure 50 Structure of modified 5-alkyl pyridine-2methyl amine with electron with-
drawing ~-CF3 group. 
An altemative amine based functionality might be the morpholine 
group (pKa -8.5). This functionality's lower solution pKa could lead to 
suppression on aggregation into the desired range. Synthesis of 
trans-2,5- or trans-2,6-disubstituted morpholines could produce 
suitable systems for analysis (Figure 51). 
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R N 
Figure 51 Possible structures of morpholine, based terminal and mid-chain 
protonating pH sensitive disruption surfactants 
As well as modifying the protonatable functionality, further 
modification of the alkyl chain sections of both the pyridine and EDTA 
molecules with branched chains, twin chains or simply synthesis of a 
greater array of chain lengths, could lead to better aggregation 
properties and more effective disruption effects. 
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6 Experimentall Procedures 
6.1 General 
a) Reagents and solvents 
Reagents were supplied by the Aldrich Chemical company or 
the Lancaster Chemical company, with some common solvents being 
sourced from Fisher Scientific. Solvents were purified and dried, with 
the appropriate drying agents using standard procedures (e.g. THF 
was dried over sodium with benzophenone as an indicator). N,N'-
dimethyl formamide (DMF), pyridine and 1 ,4-dioxan were used 
directly as supplied from Aldrich 'Sure-Seal' bottles. Other reagents 
were used as supplied, unless further purification is specified in the 
synthetic details. 
b) Chromatography 
Column chromatography was carried out using "flash column" 
silica gel 60 (0.04-0.063mm)(Merck) and thin layer chromatography 
was carried out on silica gel 60, with F254 fluorescent indicator 
(Merck), on aluminium plates. 
c) Spectroscopy 
1H NMR spectra were recorded, using a Varian Unity Inova-500 
spectrometer at 499.97 MHz: a VarianVXR-400 at 399.96 MHz: a 
Varian Unity-300 spectrometer at 299.91 MHz and a Varian Mercury-
200 spectrometer at 199.99 MHz. 13C NMR spectra were recorded on 
the Varian Unity Inova-500 at 125.6 MHz: on the VaiianVXR-400 
atl00.58 MHz: on the Varian Unity-300 at 75.4 MHz and on the 
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Varian Mercury-200 at 50.2 MHz. Mass spectra were recorded, using 
a VG Platform 11 electrospray mass spectrometer, with methanol as 
the carrier solvent and accurate masses were measured by the EPSRC 
National Mass Spectroscopy Service at the University of Swansea or by 
the Durham University mass spectroscopy service using a Micromass 
LCT electrospray mass spectrometer. Elemental analyses were 
determined using an Exeter Analytical Carlo ERBA 1106 instrument. 
Anion chromatography was carried out using a Dionex 
chromatograph. 
d) pH and Conductivity Measuerments 
Conductivity measurements were carried out using clean 
platinum electodes mounted lcm apart and connected to a Jasco 
4090 conductivity meter. pH measurements were made using a 
Coring semi-micro glass electrode, operated through a Jenway 3320 
pH meter, which was calibrated using standard buffer solutions of pH 
4, 7 and 10 at 25°C. 
e) Absorbance and luminescence 
UV absorption and transmission spectra were recorded using a 
UNICAM (UV2) spectrometer. Fluorescence measurements were 
obtained using a Fluorolog 3-11 fluorimeter. Fluorescence emission 
spectra were acquired following excitation at the given wavelength and 
were corrected for the wavelength dependence of the photomultiplier 
tube. Experiments were carried out using 3ml aliquots in standard 
quartz cuvettes with 1 cm path length. In certain cases 700).11 aliquots 
and low volume quartz cuvettes with lcm path length were used. 
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f) Determination of pKa values 
Solutions contained 0.1M NaCl to maintain an approximately 
constant ionic strength during the titrations. Titrations were run from 
alkaline to acid pH, and in each case, were shown to be reversible with 
respect to the UV wavelength shift. In a typical pH titration study, a 
known mass of 2,5-pyridine compound was dissolved in 0.1M 
aqueous NaCl (10 ml) to make a solution of approximately 0.04mM 
pyridine concentration. This solution was adjusted to pH 11.0, using 
1M NaOH stock solution. A constant volume (5 IJ.l) from 1M, 0.5M or 
0.1M HCl stock was added sequentially and the pH measured before 
and after the absorbance was recorded. A plot was made of the 
pyridine absorbance maximum as a function of pH. These curves were 
fitted using a simple iterative method under the CurveExpert 1. 3 
software and the pK values derived from the fitted curve. 
6.3.1 Determination of CMC 
Solutions for the determination of CMC were prepared, by 
dilution of a stock solution, to produce a range of solutions of the 
surfactant to be assessed at increasingly dilute concentrations. The 
stock solution was prepared, using a known mass of the required 
surfactant, and the concentration of that stock was chosen so as to be 
above the range expected for the CMC of the surfactant in question. 
The sections below describe the treatment and measurement of these 
solutions, in the determination of CMC, using conductivity 
measurements and the fluorescent pyrene micropolarity probe. 
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a) Conductivity Method 
Solutions were prepared by the method above (using ELGA Ultra 
High Quality water) and the conductivity of a 10 ml aliquot of each 
solution was then measured using the apparatus described earlier. 
Between each measurement, the platinum electrodes were rinsed with 
high purity water (4 x 25 ml) and a clean sample container used for 
each solution to prevent contamination and an increase in 
background conductivity. 
b) Pyrene Micropolarity Probe Method 
The preparation of the solutions was carried out as mentioned 
above using Purite water. A set of dilutions were also prepared, using 
0.1M NaCl in order to maintain an approximately constant ionic 
strength and to allow a comparison between the CMC values 
determined in each case. 50pl of 0.125mM pyrene solution in 
methanol was added to 2.95ml aliquots of each solution before 
fluorescence emission spectra were recorded for each solution 
(excitation 365nm). The first and fifth emission maxima were then 
used, as described, and plotted as a function of surfactant 
concentration. 
c) Micelle Disruption Experiments Using Pyrene Probe 
In a typical experiment, stock solutions of pyridine compound [ 
29 1 or [ 30 1 (0.5mM in 0.1M NaCl(aq)), CTAB (1.45mM in 0.1M 
NaCl(aq)) and 0.1M NaCl were used to make a solution (4.9ml) of 
approximately 0.013mM pyridine concentration, 1.2mM CTAB 
concentration with an approximately constant NaCl background of 
0.1M. Pyrene solution in methanol (lOOp! of 0.125mM) was then 
added, before the solution pH was adjusted to pH 10.0 using 1M 
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NaOH stock solution. A constant volume (5 )..ll) from 1M, 0.5M or 0.1M 
HCl stock was added sequentially and the pH measured before and 
after the pyrene emission spectrum (excitation 365nm) was recorded. 
The first and fifth emission maxima were then used to produce an 
intensity ratio and this was plotted as a function of pH for each 
species. 
6.3.2 Liposome Preparation 
DMPC liposomes were prepared, as described in the main text, 
by deposition 0.0125 mMol quantities (100)..ll 0.125M CHCb solution) 
of the lipid molecules onto the surface of a glassware flask from 
chloroform solution. The mixed liposome systems were prepared by 
depositing DMPC (0.0125 mMol) and the appropriate additive in the 
desired molar ratio, onto the surface of the flask from chloroform 
solution. The deposited thin film of lipid molecules was then desolved 
from the glass surface with the buffered (pH 7.2) ANTS/DPX quencher 
pair solution (1 ml). This solution was made by dissolving ANTS 
(133.5mg), DPX (474.9 mg), HEPES (29.8mg) and KCl (37.3mg) in 
25ml ofwater, adjusting the pH to 7.2 using a small quantity of the 
appropriate stock acid or base (0.1M NaOH or HCl). The crude 
liposome solution was subjected to a series of five freeze-thaw cycles, 
before being extruded through a polycarbonate membrane with a pore 
size of 1 OOnm. The resulting solution was then passed through a 
Sephadex PD-10 pre-packed column and eluted with a pH 7.2 buffer 
solution, containing 5mM HEPES and 1 OOmM KCl. The liposome 
solution (-2.5ml) collected from the column was then used in the 
ANTS/DPX liposome leakage assay measurements. 
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6.3.3 ANTS/DPX Liposome Fluorescence Assay 
In a typical experiment, quencher pair filled liposome solution 
[20!-11 pH7.2 (see section 6.3.2 above)] was added to a buffer solution 
(2.48ml), (pH 7.2 HEPES 5mM KCl 100mM, pH 6.1 MES 5mM KCl 
100mM, or pH 4.8 acetate 5mM KCl 100mM) in a standard 3ml 
quartz fluorescence cuvette. The fluorescence emission spectrum of 
this solution was then recorded (excitation 353 nm). Following the 
collection ofthe emission spectrum, 0.5 ml ofTritonX-100 (0.1M) 
solution was added and the cuvette agitated. The emission spectrum 
was then recorded again and the maximum fluorescence intensity, at 
515nm, for the two spectra compared. The experiments were repeated 
and mean values for the percentage difference are shown in the 
Tables. 
6.2 Synthetic Procedures 
6.3.1 Pyridine Syntheses, Precursors and Modifications 
5-Methylpyridine-2-carboxylic acid 114. 
0 
OH 
[ 2 1 
2,5-Lutidine (5g, 46.65 mmol), was combined with selenium 
dioxide (9.3g 83.8mmol). in pyridine (20ml). The reaction mixture was 
heated to reflux for 4h. During this time, the solution turned from 
colourless, through red to black. The black solution/ suspension was 
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filtered through celite® filter agent and the residue was thoroughly 
washed, with pyridine (50ml) and water (75ml). The filtrate was 
charged to a 250ml two-neck round bottom flask fitted for steam 
distillation. Around 11 of water was used in the steam distillation, and 
after removal of the steam line, the mixture was distilled to dryness 
under reduced pressure. The dry residue, was treated with ethyl 
acetate (75ml) and refluxed with activated carbon (2g) before being 
filtered hot, through a small celite® plug. This plug was washed, with 
more hot ethyl acetate (50ml), the solvent was then removed under 
reduced pressure, and the solid residue recrystallised from water 
yielding an orange crystalline solid. (3.2g, 50%) 
m. p. 168-1 70°C. (Lit. 168-169°C 114) 
OH ppm (CDCb): 2.48 (3H, s, CH3), 7. 78 (1H, d, J = 8 Hz, H 4), 8.16 
(1H, d, H 3), 8.48 (1H, s, H 6). 
8c ppm (CD30D): 17.38 (CH3). 124.99 (C 4), 138.8 (C 5). 139.95 (C 3). 
145.19 (C 2). 147.87 (C 6) 165.76 (C02H). 
MS (ES+) m/z 138 (MH+). 160 (MNa+). 
Anal. C7H7N02. 1/BH20 calculated C, 60.32%, H, 5.24%, N, 10.05%, 
Found C, 60.56%, H, 5.34%, N, 10.08%. 
General procedure for formation of 5-bromomethyl pyridines via 
N-bromosuccinimide (NBS) brominationll5-11B, 
The 5-methylpyridine (11.6mmol), was added along with NBS 
(11.6 mmol for predominantly monobromomethyl pyridine], or 34.8 
mmol for predominantly dibromomethyl pyridine), in carbon 
tetrachloride (20 ml). The contents of the flask were heated to reflux, 
before 2,2'-azobis (2-methylpropionitrile) (AIBN) (~5mg) was added to 
initiate the reaction. Reaction progress, was monitored by 1H NMR, 
from which levels of both bromination products, and the relative 
amount of remaining starting material was determined. This was 
determined by integration of the CH3, CH2Br and CHBr2 proton NMR 
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resonances at 2.4 ppm, 4.4 ppm and 6.6ppm respectively. After 
stirring under reflux, for 14-18h, the reaction mixture was filtered, 
and washed with carbon tetrachloride before being cooled. The cooled 
solution was washed with aqueous sodium hydrogencarbonate 
solution (2x25ml). in order to remove any remaining succinimide. The 
organic layer was dried, using magnesium sulphate and the solvent 
removed under reduced pressure, to leave the crude product. This 
crude mixture was purified using flash column chromatography on 
silica. The solvent system used was 10% methanol in DCM. 
2-Bromo 5-bromomethyl pyridine 119. 
Lit. m.p. 62°-63°Cll9 
m.p. 61 °-63°C 
Br 
Rf. 0.53 (5% MeOH in DCM) 
Br 
BH ppm (CDCb):4.36, (2H, s, CH2Br), 7.4 (1H, d, J =8Hz, H 3). 7.55 
(lH, dd, J =8Hz, J =3Hz, H 4). 8.3 (lH, d, J = 3Hz, H 6 ). 
MS (ES+): m/z 249.9 (MH+), 272 (MNa+) 
2-Bromo 5-dibromomethyl pyridine 120. 
Br 
Br 
Br 
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Lit. m.p. 91°C 
m.p. 89o-92oc120 
Rf. 0.61 (5% MeOH in DCM) 
OH ppm (CDCb): 6.55 (1H, s, CHBr2). 7.49 (1H, d, J =8Hz. H 3), 7.83 
(lH, d, H 4). 8.39 (1H, s, H 6 ). 
MS (ES+): m/z 328 (MH+). 
5-Methylpyridine-2-carbonitrile 121.122. 
[ 1 ] 
c~ ~N 
2-Bromo-5-methylpyrtdine (2g, 11.6 mmol), copper (I) cyanide 
(4.157g, 46.4mmol) and tetraethylammonium cyanide (1.81g 
11. 6mmol). were charged to a round bottom flask with dry 1 ,4 dioxane 
(30ml) and degassed by a freeze/pump/thaw method, before 
tris(dibenzylideneacetone)-dipalladium [Pd2(dba)3] (0.26g, 0.465 
mmol) and diphenyl-phosphinoferrocene (DPPF) (1.025g, 1.85mmol), 
were added. The reaction mixture was heated to reflux under an inert 
atmosphere for 12h. After this time, the mixture was diluted with 
ethyl acetate (50ml). and filtered through celite®. The filtered solution 
was washed with saturated, aqueous sodium bicarbonate solution 
(50ml). separated and dried over magnesium sulphate. The solvent 
was removed under reduced pressure. The resulting crude product, 
(deep brown oil and crystals) was recrystallised from petroleum ether 
to leave a yellow crystalline solid. 
Lit. m. p. 76°-77°C(petroleum ether) 123; 73°-75°C (hexane) 124. 
m.p. 74.2°-76.4°C 
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OH ppm (CDCb): 2.45 (3H, s, CH3), 7.62 (2H, s, H 3&4). 8.56 (1H, s, H 
6). 
General procedure for the synthesis of 2-alkylacrylaldehydes 
(acroleins)125.12G. 
The required, n-alkyl aldehyde (0.02mol), N,N-
dimethylmethyleneammonium Chloride (0.02mol) and water were 
combined in a 1 OOml round bottom flask. The mixture was stirred 
and heated to 75°C for 24h. After this time, the two phases were 
separated, and the aqueous layer extracted with hexane (3x50ml). 
The organic phases were combined, and the solvent evaporated. The 
remaining light yellow organic oil was fractionally distilled under 
reduced pressure, yielding the product as a clear colourless oil. 
Previously synthesised and reported compounds were characterised 
by comparison of b. p. 126 All products were additionally characterised 
by l H and l3C NMR and ESMS 
2-Hexylacrylaldehyde 125. 
Lit. b.p.: 76°C/20mm Hg. 125 
b.p.: 38°C/ 2mm Hg 
~0 
[ 10 I 
OH ppm (CDCb): 0.81 (3H, t, J = 6.6Hz, CH3), 1.20 (8H, m, -(CH2)4-
CH3). 2.16 (2H, t, J = 7.6Hz, -CH2-C(COH)=CH2), 5.91 (lH, s. C=CH2 
trans), 6.17 (lH, s, C=CH2 cis). 9.46 (lH, s, CHO). 
108 
Chapter 6 
Be ppm (CDCb): 14.21 (CHs). 22.75 (CH2). 27.89 (CH2), 27.95 (CH2), 
29.15 (CH2), 31.78 (CH2). 134.02 (C=CH2). 150.68 (C=CH2). 194.94 
(CHO). 
MS (ES+) m/z 140.2 (MH+). 163.5 (MNa+) 
2-Decylacrylaldehyde 126. 
Lit. b.p.: 70°-75°C/1mm Hg. 126 
b.p.: 89°C/2.5mm Hg 
[ 11 1 
OH ppm (CDCb): 0.80 (3H, t, J = 6.7Hz, CHs). 1.18 (14H, m, -(CH2h-
CH2-CHs). 1.37 (2H, m, CH2-CHs). 2.16 (2H, t, J = 7.5Hz, CH2-
C(COH)=CH2). 5.91 (1H, s, C=CH2 trans). 6.17 (lH, s, C=CH2 cis). 9.46 
(1H, s, CHO) 
Be ppm (CDCb): 14.34 (CHs). 22.91 (CH2). 24.93 (CH2). 27.99 (CH2). 
29.30 (CH2), 29.55 (CH2), 29.63 (CH2), 29.8 (CH2), 29.82(CH2), 32.13 
(CH2). 134.15 (C=CH2), 150.68 (C=CH2), 195.06 (CHO). 
MS (ES+) m/z 196.4 (MH+) 
General procedure for the formation of ( IE)-2-alkylacrylaldehyde 
dimethylhydrazones 127. 
The required, 2-alkyl propenal (0.025 mol). N,N-dimethyl 
hydrazine (0.05mol) and a catalytic amount of glacial acetic acid 
(-100-250 pl) were combined under an inert atmosphere, in diethyl 
ether (30ml) and the mixture was boiled under reflux, for 45min. The 
solution was cooled, and washed in turn, with water (50ml) and 
saturated sodium chloride solution (50ml). The ethereal solution was 
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dried over anhydrous MgS04 and the solvent removed under reduced 
pressure. The resultant product was typically a yellow oil, which was 
used directly without further purification. 
( lE)-2-Hexylacrylaldehyde dimethylhydrazone. 
~ 
N 
I 
/N~ 
[ 12] 
OH ppm (CDCb): 0.81 (3H, m, CH2-CH3), 1.22 (6H, m, -(CH2)3-). 1.42 
(2H, m, CH2-CH3). 2.24 (2H, t, -CH2-C=CH2). 2. 77 (6H, s, N-(CH3)2). 
4.97 ( 1H, d, J = 1.5Hz, C=CH2). 5.02 (1H, d, J = 1.5Hz, C=CH2). 6.93 
(1H, s, CH=N). 
oc ppm (CDCb): 14.3 (CH3). 22.85 (CH2). 28.49 (CH2), 29.45 (CH2), 
31.24 (CH2). 31.97 (CH2). 42.95 (N-(CH3)2), 114.56 (=CH2). 136. 78(C=). 
147.20(C=N). 
MS (ES+) m/z 182.1 (MH+). 205.9 (MNa+) 
( lE)-2-Decylacrylaldehyde dimethylhydrazone. 
[ 13 ] 
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OH ppm (CDCb): 0.81 (3H, t, J = 6.6Hz, CHz-CH3). 1.21 (14H, m,-
(CH2 )7-), 1.42 (2H, m, -CH2-CH3). 2.24 (2H, t, J = 7.2Hz, -CH2-C=CHz), 
2.76 (6H, s, N-(CH3)2). 4.97 ( 1H, d, J = 1.5Hz, C=CHz). 5.02 (1H, d, J 
= 1.5Hz, C=CHz). 6.93 (1H, s, CH=N). 
oc ppm (CDCb): 13.1 (CH3). 21.68 (CHz). 27.28 (CHz). 28.29 (CHz). 
28.36 (CHz). 28.46 (CHz). 28.60 (CHz). 28.64 (CHz). 29.99 (CHz). 30.92 
(CHz). 41.78 (N-(CH3)2). 113.46 (=CHz). 135.82(C=). 145.93(C=N). 
MS (ES+) m/z 238.7 (MH+). 262.1 (MNa+) 
General procedure for the formation of 2-cyano,5-
alkylpyridines7l.l27 
(1E)-2-Alkylacrylaldehyde dimethylhydrazone (0.06 mol) was 
combined with trimethylamine (17.5g, 0.12 mol), and acetonitrile 
(50ml) under an inert atmosphere. Chloroacrylonitrile (0.07 mol). was 
added to the solution and this mixture was heated to 75°C with 
stirring for 8-12 h. At the end of this period, a colour change from the 
initial light yellow to dark brown was observed, along with a small 
amount of a pale precipitate. The solution was filtered to remove the 
precipitate, and concentrated by evaporation. The viscous residue 
was dissolved in dry 1,4-dioxane (100ml) and a stream of dry HCl gas 
was bubbled through this solution until the dioxane was acidic. The 
acidified solution, was stirred for 30min, the dioxane evaporated, and 
the residue dissolved in chloroform (50ml). This chloroform solution, 
was washed in turn, with saturated aqueous NaHC03 solution, 
(2x50ml). Distilled water (2x50ml) and saturated aqueous NaCl 
solution (50ml). The organic phase, was separated and dried over 
MgS04, before the solvent was removed under reduced pressure. The 
product in each case was a pale brown waxy solid. 
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5-Hexy!pyridflne-2-culbonfltrile. 
CN 
[ 14] 
OH ppm (CDCb): 0.79 (3H, m, CH3). 1.22 (6H, m, -(CH2)3-). 1.56 (2H, 
m, CH2-CH3). 2.58 (2H, t, J = 8.5 Hz, -CH2-py). 7.56 (2H, m, H3, H 4). 
8.45 (1H, s, H 6). 
oc ppm (CD30D): 14.21 (CH3). 22.89 (CH2). 30.81 (CH2). 31.64 (CH2). 
31.67 (CH2). 33.27 (CH2). 117.66 (CN). 128.34 (C 4), 131.21 (C 5). 
136.82 (C 3), 142.73 (C 2), 151.54 (C 6). 
MS (ES+) m/z 188.4 (MH+), 211.2 (MNa+) 
5-Decylpyridine-2-carbonitrile. 
~ 
N CN 
[ 15] 
OH ppm (CDCb): 0. 78 (3H, m, CH3). 1.18 (14H, m, -(CH2)7-). 1.57 (2H, 
m, CH2-CH3), 2.68 (2H, t, J = 7.5 Hz, -CH2-py). 8.30 (2H, m, H3, H 4). 
8.87 (1H, s, H 6). 
oc ppm (CD30D): 14.30 (CH3), 22.85 (CH2), 29.33 (CH2), 29.43 (CH2). 
39.52 (CH2). 29.70 (CH2). 29.76 (CH2), 30.52 (CH2), 32.07 (CH2). 33.24 
(CH2). 119.86 (CN). 128.66 (C 4), 136.89 (C 5), 142.73 (C 3), 147.78 (C 
2). 159.51 (C6). 
MS (ES+) m/z 244.2 (MH+). 267.5 (MNa+) 
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5-Hexylpyridine-2-carboxamide. 
# 
N 
0 
[ 22 I 
A solution of 5-hexylpyridine-2-carbonitrile (3g -16 mMol) in 
ethanolic potassium hydroxide, (-15wt%) was boiled under reflux for 
8-10 h. The solution was then concentrated, acidified with 
hydrochloric acid solution (1M) and extracted with diethyl ether 
(3x50ml). The ethereal solution, was dried over MgS04 and the 
solvent removed under reduced pressure to give an orange crystalline 
soild. The crystals were of such size and quality as to allow single 
crystal, X-ray structural analysis to be carried out. (see Appendix 1 for 
X-ray diffraction data). 
m.p. 134°-136°C 
OH ppm (CDCb): 0. 79 (3H, m, CH3), 1.22 (6H, m, -(CH2)3-), 1.56 (2H, 
m, CH2-CH3). 2.58 (2H, t, J = 8.5 Hz, -CH2-py). 7.69 (1H, s, H3). 7.72 
(lH, s, H 4). 8.25 (2H, s br, NH2). 8.45 (lH, s, H 6). 
Oc ppm (CD30D): 14.21 (CH3), 22.89 (CH2). 30.81 (CH2). 31.64 (CH2). 
31.67 (CH2). 33.27 (CH2). 124.97 (C 4), 136.82 (C 3). 143.58 (C 2), 
145.37 (C 5). 148.95 (C 6), 166.02 (CONH2). 
MS (ES+) m/z 206.3 (MH+) 
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5-Hexylpyridine-2-carboxylic acid7l.l27. 
OH 
[ 16] 
A solution of 5-hexylpyridine-2-carbonitrile in ethanolic 
potassium hydroxide, (~20wt%) was boiled under reflux for 24 h. The 
solution was then concentrated, acidified with hydrochloric acid 
solution (1M) and extracted with diethyl ether (3x50ml). The ethereal 
solution was dried over MgS04 and the solvent removed under 
reduced pressure to give a waxy solid. 
m.p. 128°-13PC 
OH ppm (CDCb): 0. 79 (3H, m, CH3), 1.22 (6H, m, -(CH2)3-). 1.56 (2H, 
m, CH2-CH3), 2.58 (2H, t, J = 8.5 Hz, -CH2-py), 7.56 (2H, m, H3, H 4), 
8.45 (1H, s, H 6). 
oc ppm (CD30D): 14.21 (CH3). 22.89 (CH2). 30.81 (CH2). 31.64 (CH2), 
31.67 (CH2). 33.27 (CH2). 128.34 (C 4), 131.21 (C 5). 136.82 (C 3). 
142.73 (C 2). 151.54 (C 6) 176.26 (COOH). 
5-Decylpyridine-2-carboxylic acid. 
~0 
OH 
[ 17 I 
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This product was formed by the hydrolysis of 5-decylpyridine-2-
carbonitrile, using the same reaction conditions as above. 
OH ppm (CDCb): 0. 78 (3H, m, CH3), 1.18 (14H, m, -(CH2)7-), 1.57 (2H, 
m, CH2-CH3), 2.68 (2H, t, J = 7.5 Hz, -CH2-py), 8.30 (2H, m, H3, H 4), 
8.87 (lH, s, H 6). 
Be ppm (CD30D): 14.30 (CH3), 22.85 (CH2), 29.33 (CH2), 29.43 (CH2), 
39.52 (CH2), 29.70 (CH2), 29.76 (CH2), 30.52 (CH2), 32.07 (CH2), 33.24 
(CH2), 128.66 (C 4), 136.89 (C 5), 142.73 (C 3), 147.78 (C 2), 159.51 
(C 6), 173.48 (COOH) 
Typical procedure to 5-alkyl-N-alkylpyridine-2-carboxamides 
5-Alkylpyridine 2-carbox:ylic acid (10mmol), was combined with 
1-(3-dimethylaminopropyl) -3-ethylcarbodiimide (EDCI) ( 1 Ommol) and 
hydroxybenzotriazole, (- 0.06mmol), in dry dichloromethane (20 ml), 
under an inert atmosphere. The appropriate amine, (11mmol, 1.1 
equivalents), was added to this mixture. The mixture was then stirred 
for 12h., when the solution was washed successively with, water 
(50ml) aqueous hydrochloric acid solution (0.1M, 50ml), and finally 
aqueous sodium bicarbonate solution (0.1M, 50ml). After this, the 
organic layer was dried over calcium chloride, and the solvent 
removed under reduced pressure. The residue in each case, was a 
light orange oil or waxy solid. 
5-Methyl-N -octylpyridine-2-carboxamide. 
~ 
N 
0 
H 
N 
[ 3] 
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OH ppm (CDCb): 0.81 (3H, t, J = 7Hz, CH2CH3), 1.20 (lOH, m, [CH2]s), 
1.56 (2H, m, CH2CH3), 2.33 (3H, s, 5-CH3), 3.39 (2H, q, J = 6 Hz, 
NHCH2), 7.55 (1H, d, J =8Hz, H 4), 8.02 (1H, d, H3), 8.29 (1H, s, H 
6). 
& ppm (CDCb): 17.93(CH3), 22.34 (CH3), 26.49 (CH2), 30.87 (CH2), 
33.05 (CH2), 33.14 (CH2), 33.53(CH2), 35.64(CH2), 43.26 (CH2NH), 
125.60 (C 3), 139.95 (C 5), 141.47 (C 4), 151.49 (C 2), 152.29 (C 6), 
168.24 (CO), 
MS (ES+) m/z 249 (MH+), 271 (MNa+) 519 ((2M)Na+). 
Acc.MS (ES+) Found: m/z 249.1974 (MH+). C1sH2sN20 requires: 
249.1967 (MH+) 
5-MethyU-N-he:xylpyridine-2-carbo:xamide. 
~ 
N 
0 
H 
N 
[ 4] 
OH ppm (CDCb): 0.55 (3H, t, J = 6.5 Hz, CH2CH3), 0.95 (6H, m, [CH2]3), 
1.29 (2H, m, CH2CH2CH3), 2.03 (3H, s, 5-CH3), 3.15 (2H, q, J = 6.5 
Hz, CH2NH), 7.28 (1H, d, J =8Hz, H4), 7.78 (1H, d, H3), 7.87 (1H, t, 
broad NH), 8.01 (1H, s, H6). 
Oc ppm (CDCb): 13.96 (CH3), 18.32 (CH3), 22.52 (CH2), 26.66 (CH2), 
29.69 (CH2), 31.49 (CH2), 39.32 (CH2NH), 121.59 (C 3), 135.94 (C 5), 
137.42 (C 4). 147.74 (C 2}. 148.38 (C 6). 164.26 (CO). 
MS (ES+) m/z 22l(MH+), 243 (MNa+). 
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Acc.MS (ES+) Found: m/z 221.1653 (MH+) C13H21N20 requires: 
221.1654 (MH+). 
5-Hexyl-N -(6-hydroxyhexyl)pyridine-2-carboxamide. 
p 
N 
0 
[ 18] 
H 
N 
OH 
OH ppm (CDCb): 0.81 (3H, m, CH2CH3), 1.24 (14H, m, [CH2]?), 1.55 
(2H, m, CH2CH2CH3), 2.59 (2H, t, J = 8 Hz, CH2-py), 3.38 (2H, q, J = 5 
Hz, CH2NH). 3.56 (2H, t, J =4Hz, CH2-0H), 7.58 (1H, dd, J =8Hz, J 
= 2Hz, H 4), 8.02 (1H, d, J =8Hz, H 3), 7.95 (1H, br t, NH), 8.27 (1H, 
d, J =2Hz, H 6). 
MS (ES+) m/z 307(MH+), 
5-Decyl-N -(6-hydroxyhexyl)pyridine-2-carboxamide. 
H 
N 
OH 
0 
[ 19] 
OH ppm (CDCb): 0.80 (3H, m, CH2CH3), 1.18 (22H, m, [CH2]11), 1.45 
(2H, m, CH2CH2CH3), 2.53(2H, t, J = 8 Hz, CH2-py), 3.38 (2H m, 
CH2NH). 3.56 (2H, m, CH2-0H), 7.15 (1H, br d, J H4), 7.39 (1H, br d, 
H3), 8.27 (1H, s, H6). 
MS (ES+) m/z 363(MH+), 385 (MNa+). 
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Typical Procedure for Borane Reduction of amides 
Between 0.2mmol and 1mmol, ofthe amide to be reduced was 
charged to a clean, dry, round bottom flask under an argon 
atmosphere. To the amide, was added borane THF complex (20-50ml 
of a 1M solution in THF). The solution was heated to a gentle reflux, 
with stirring for 36-48h. Mter this time, the reaction was quenched 
with methanol (50-1 OOml) and the solvent removed. The residue was 
treated with methanol (4xl0ml), being dried under vacuum between 
each treatment. At this point, preliminary analysis using TLC, I H 
andl3C NMR was undertaken. It was found that in almost all 
circumstances, a further treatment of this crude product with borane 
THF, was required for complete amide reduction. Therefore, further 
borane THF complex was added (lM, 50ml), and the solution heated 
to reflux under an argon atmosphere, for a further 12-24 h. The 
reaction mixture was treated with methanol as before and analysis 
carried out to detect any trace of amide. The residue, was then boiled 
under reflux in aqueous hydrochlmic acid solution (3M, 75ml), for 4-
6h. The acidic solution was neutralised with aqueous potassium 
hydroxide solution (3M), saturated with K2C03 and extracted with 
diethyl ether (3x50ml). The extract, was dried over magnesium 
sulphate, filtered, and the solvent removed under reduced pressure to 
yield an oily product. 
N -[(5-Methylpyridin-2-yl)methyl)-N -octylamine. 
H 
# N 
N 
[ 5 ] 
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Reduction of 2-octylamido 5-methyl pyridine (0.25g, 1mmol) 
yielded a pale orange oil, ( 0.15g, 64%). 
01-1 ppm (CDCb): 0.77 (3H, t, J =7Hz, CH2CH3). 1.19 (10H, m, [CH2lsl. 
1.42 (2H, m, J = 7Hz, CH2CH3), 2.23 (3H, s, 5-CH3). 2.55 (2H, t, J = 7 
Hz, NHCH2). 3.78 (3H, s, CH2 2), 7.10 (1H, d, J =8Hz, H 4). 7.37 (1H, 
d, J =8Hz, H 3). 8.29 (1H, s, H 6). 
Oc ppm (CDCb): 17.14 (CH3). 21.14 (CH3). 25.70 (CH2). 30.42 (CH2). 
32.30 (CH2). 32.74 (CH2). 33.22 (CH2). 34.88 (CH2), 52.75 (CH2NH), 
58.12 (CH2NH). 124.84 (C 3), 134.17 (C 5). 139.98 (C 4). 152.64 (C 6). 
160.03 (C 2), 
MS (ES+) m/z 235 (MH+), 257 (MNa+). 
Acc.MS (ES+) Found: m/z 235.2177 (MH+) C1sH25N2 requires: 
235.2174 (MH+) 
N -[(5-Metbylpyridin-2-yl)metbyl]-N -hexylamine. 
The general reduction procedure was again employed to reduce 
(0.22g, 1mmol) of 2-he:xylamido 5-methyl pyridine and yielded a pale 
orange oil, ( 0.12g, 58%.) 
01-1 ppm (CDCb): 0.79 (3H, t, J =7Hz, CH2CH3), 1.19 (6H, m, [CH2]3), 
1.44 (2H, m, CH2CH2CH3), 2.22 (3H, s, 5-CH3), 2.56 (2H, q, J = 7Hz, 
CH2CH2NH), 3. 78 (2H, s, CH2NH) 7.13 (lH, d, J = 7.5 Hz, H 4). 7.38 
(1H, d, H 3), 8.29 (1H, s, H 6). 
Oc ppm (CDCb): 14.21 (CH3), 18.25 (CH3), 22.78 (CH2), 27.23 (CH2), 
30.34 (CH2), 31.96 (CH2), 49.9 (CH2NH), 55.29(CH2NH), 121.94 (C 3), 
131.28 (C 5), 137.09 (C 4), 149.8 (C 2). 157.26 (C 6), 
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6-{[(5-Hexylpyridin-2-yl)methyl)amino}hexan-1-ol. 
# 
N 
[ 20 I 
H 
N 
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OH 
BH ppm (CDCb): 0. 79 (3H, m, CH2CH3), 1.25 (14H, m, [CH2hl. 1.55 
(2H, m, CH2CH2CHs). 2.59 (4H, m, -CH2-py, N-CH2-py). 3.38 (2H, q, J 
= 5Hz, CH2NH). 3.56 (2H, t, J =4Hz, CH2-0H). 7.57 (lH, dd, J = 8 
Hz, J = 2 Hz, H 4). 8.12 (lH, d, J = 8 Hz, H 3). 8.26 (1H, d, J = 2 Hz, H 
6). 
Be ppm (CDsOD): 14.30 (CHs). 22.85 (CH2). 25.43 (CH2), 29.33 (CH2). 
29.70 (CH2). 29.76 (CH2). 30.52 (CH2). 32.07 (CH2). 33.24 (CH2). 36.44 
(CH2). 48.67 (CH2NH). 53.32 (CH2NH). 61.01 (CH2-0H). 128.66 (C 4), 
136.89 (C 5). 140.73 (C 3). 147.78 (C 2), 149.53 (C 6). 
MS (ES+) m/z 293(MH+). 
6-{[(5-decylpyridin-2-yl)methyl]amino}hexan-1-ol. 
H 
N 
OH 
[ 21 I 
BH ppm (CDCb): 0.80 (3H, m, CH2CH3). 1.18 (22H, m, [CH2h d. 1.45 
(2H, m, CH2CH2CHs). 2.53(4H, m, -CH2-py, N-CH2-py). 3.38 (2H m, 
CH2NH). 3.56 (2H, m, CH2-0H), 7.15 (lH, br d, H 4). 7.39 (lH, br d, H 
3), 8.27 (1H, s, H 6). 
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Oc ppm (CD30D): 14.30 (CH3). 22.85 (CH2). 25.43 (CH2), 25.83 (CH2). 
27.63 (CH2). 29.12 (CH2). 29.33 (CH2). 29.70 (CH2), 29.76 (CH2). 30.52 
(CH2). 31.76 (CH2). 32.07 (CH2). 33.24 (CH2). 36.44 (CH2), 47.97 
(CH2NH), 52.82 (CH2NH). 59.51 (CH2-0H), 126.16 (C 4), 138.59 (C 5), 
140.20 (C 3). 145.58 (C 2). 14 7.33 (C 6). 
MS (ES+) m/z 372(MNa+) 
GeneraU 1Pll'oced1Lll.ll'e for lth.e Synlth.esil.s of N,N,N-trimet:h.y!-2-{[(5-
alkylpyll'idil.n-2-yU)methyl]amino }h.e:x:an-1-aminium cll:doll'id.e 
Surfactants. 
The synthesis of these products, from the pyridine amino 
alcohols was carried out in several steps. However, as the intermediate 
products were not separated, and some stages were routine protection 
I deprotection reactions, only the final product was characterised 
fully. However, some characterisation of the intermediates was carried 
out (usually 1 H NMR). and representative examples, for each stage of 
the reaction process are given. The first step of the synthesis, was the 
BOC protection of the amine. The 6-{[(5-alkylpyridin-2-
yl)methyl]amino}hexan-1-ol (0.1mmol}, was combined with BOC 
anhydride (0.15mmol). in methanol (20ml) at room temperature for 6-
8 hr. or until complete conversion of starting material was indicated 
by TLC. The solvent was removed, and the residue dried under 
reduced pressure, before the next step of the reaction was carried out. 
The mesylation of the alcohol, was performed by dissolving the BOC 
protected intermediate (0.1mmol}, in DCM (35ml). under an inert 
atmosphere and cooling the solution to ooc using an ice/salt bath, 
before adding disopropylethylamine (DIPEA) (3.5 mmol). and 
methanesulphonyl chloride (1.5mmol). The reaction mixture, was 
maintained at ooc during addition, and for a further 4hr. Before 
being allowed to return to room temperature, the reaction was 
quenched with aqueous NaHC03 (25ml 0.1M). The organic layer was 
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separated and washed with aqueous citrtc acid solution ( 10 % 3 x 
25ml), then dried over MgS04. Ethanolic trtmethylamine solution 
(25ml 1 M), was then added to this residue, and the mixture stirred for 
3hr before the solvent was removed. The BOC protection group, was 
removed from the amine in the usual way, by treatment with TFA. 
Crude charactertsation was then carried out (IH, I3C NMR and ESMS). 
The product was then dissolved in water, mixed with DOWEX® 1X8 
strong chlortde exchange resin (3.5meq/g [dry]). This mixture was 
stirred, filtered to remove the resin and washed with water. The 
aqueous solution obtained, was freeze-dried to yield the yellow-brown 
waxy product. These products [ 29 1 and [ 30 1 were charactertsed by 
IH, I3C NMR, accurate ESMS and anion chromatography, which 
indicated the presence of chloride as the only anion. 
Boc 
N 
OH 
[ 231 
OH ppm (CDCb): 0. 79 (3H, m, CHzCH3), 1.22 (14H, m, [CHz]?). 1.39 
(18H, s, t-Bu x 2) 1.54 (2H, m, CHzCH2CH3), 2.54 (2H. m, -CH2-py), 
3.19 (2H. m. NBoc-CH2-py), 3.61 (2H, m, CH2-0H), 3.97 (2H, m, 
CH2NBoc), 7.07 (1H, m, H 3), 8.12 (1H, m, H 4), 8.24(1H, m, H 6). 
Boc 
N 
OMs 
[ 251 
OH ppm (CDCb): 0.79 (3H, m, CHzCH3), 1.22 (14H, m, [CHzH. 1.41 
(9H, s, t-Bu) 1.54 (2H, m, CHzCH2CH3), 2.54 (2H, m, -CH2-py). 2.92 
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(3H, s, CH3-S), 3.08 (2H, m, NBoc-CH2-py), 4.12 (2H, m, CH2NBoc), 
7.07 (lH, m, H 3), 8.12 (lH, m, H 4), 8.24(1H, m, H 6). 
MS (ES+) m/z 470.3 (MH+) 
~ 
N 
[ 27] 
Boc 
N + 
OH ppm (D20): 0.68 (3H, m, CH2CH3), 1.12 (14H, m, [CH2]7), 1.27 (2H, 
m, CH2CH2CH3), 1.38 (9H, s, t-Bu) 2.65 (2H, m, -CH2-py,), , 2.94 (9H, 
s, (CH3)3-N+), 3.10 (2H, m, NBoc-CH2-py,), 3. 77 (2H m, CH2NBoc), 
4.39 (2H s, CH2-N+-Me3 ),7.78 (1H, br d, H 4), 8.21 (lH, br d, H 3), 
8.58 (1H, s, H 6). 
MS (ES+) m/z 434.7 (MH+) 
N ,N ,N-Trimethyl-2-{[(5-hexylpyrldin-2-yl)methyl]amino}hexan-1-
aminium chloride. 
H 
N 
[ 29] 
OH ppm (D20): 0.68 (3H, m, CH2CH3), 1.12 (14H, m, [CH2hl. 1.27 (2H, 
m, CH2CH2CH3), 2.65 (2H, m, -CH2-py,), , 2.94 (9H, s, (CH3)3-N+), 3.01 
(2H, m, HN-CH2-py,), 3.17 (2H m, CH2NH), 4.39 (2H s, CH2-N+-Me3 
), 7. 78 (1H, br d, H 4), 8.21 (1H, br d, H 3), 8.58 (1H, s, H 6). 
Be ppm (CD30D): 13.47 (CH3), 22.00 (CH2), 22.69 (CH2), 25.12 (CH2), 
25.38 (CH2), 25.43 (CH2), 27.85 (CH2), 29.64 (CH2), 30.86 (CH2), 31.96 
(CH2), 47.22 (CH2NH), 48.32 (CH2NH), 52.92 (CH3N+-),52.95 (CH3N+-
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),52.98 (CH3N+-), 66.58 (-CH2-N+-), 127.86 (C 4), 130.37 (C 5), 133.25 
(C 3), 143.00 (C 2), 147.17 (C 6). 
Acc.MS (ES+) Found: m/z 334.3190 (M+) C21H4oN3 requires: 334.3222 
(M+). 
N,N,N-Trimethyl-2-{[(5-decylpyridin-2-yl)methyl]amino}hexan-1-
aminium chloride. 
e 
Cl 
[ 301 
OH ppm (D20): 0. 71 (3H, m, CH2CH3), 1.16 (22H, m, [CH2l11l. 1.32 (2H, 
m, CH2CH2CH3), 2.53 (2H, m, -CH2-py,), , 2.87 (9H, s, (CH3)3-N+), 2.99 
(2H, m, HN-CH2-py,), 3.20 (2H m, CH2NH), 4.35 (2H s, CH2-N+-Me3 
),7.71 (1H, br d, H 4), 8.11 (1H, br d, H 3), 8.46 (lH, s, H 6). 
& ppm (CD30D): 13.32 (CH3), 18.18 (CH2), 22.72 (CH2), 22.85 (CH2), 
25.49 (CH2), 25.63 (CH2), 25.78 (CH2), 29.02 (CH2), 29.28 (CH2), 
29.54 (CH2), 31.15 (CH2), 31.89 (CH2), 32.36 (CH2), 38.40 (CH2), 
50.65 (CH2NH), 51.72 (CH2NH), 52.4 7 (CH3N+-),52.49 (CH3N+-),52.50 
(CH3N+-), 66.42 (-CH2-N+-), 127.86 (C 4), 130.37 (C 5), 133.25 (C 3), 
143.15 (C 2), 14 7.28 (C 6). 
Acc.MS (ES+) Found: m/z 390.3847 (M+) C25H4sN3 requires: 390.3848 
(M+). 
124 
Chapter 6 
6.3.2 EDTA andl ][J)TJP.A Ligand§ and Complexe& 
2-[Carboxy(2-{carboxy[((R)-( + )-1-(2-
naphthyl)ethylamino )carbonyl] amino }ethyl) amino ]ethyl[((R)-( + )-1-
(2-naphthyl)ethylamino)carbonyl)carbamic acid. 
[31] 
N, N"-bis[2- (2, 6-dioxomorpholino )ethyl]glycine (DTPA 
dianhydride) 0.357g (1mmol), was combined with 5ml of dry DMF, 
under an argon atmosphere. (R)-(+)-2-Naphthyl ethyl amine solution 
0.513g (3mmol) in CHCb (2ml), was then added, dropwise, over 15 
min. This mixture was stirred for 30min, until the initially observed 
precipitate dissolved. The solution was then heated to 50°C under 
reflux for 14h. After this time, the solvent was removed under reduced 
pressure. The solid white residue, was washed with water (3x20ml) 
and ether (3x50ml). The product, a white crystalline solid, was then 
dried under reduced pressure and characterised by elemental analysis 
and 1H and I3C NMR. 
m.p. in excess of 250°C 
OH ppm (CD30D): 1.74 (6H, d, J =7Hz, CH3), 3.28 (4H, m, -N-CH2 -), 
3.33(4H, m, -N-CH2-), 3.69 (6H, s, CH2-COOH), 3.56 (4H, s, CH2-
125 
Chapter 6 
CONH) 4.62 (2H, m, -CH-Ar.), 7.50 (2H, m, Ar), 7.54 (2H, m, Ar), 7.93 
(6H, m, Ar), 8.10 (4H, m, Ar). 
0c ppm (CD30D): 24.25 (CH3). 48.93 (CH2NH). 53.34 (-N-CH2-COOH). 
53.36 (-N-CH2-COOH). 59.32 (-N-CH2-CONH), 60.04 (Naph-CH-NH). 
123.78 (C 6). 124.41 (C 7), 125.45 (C 1). 125.91 (C 4). 127.42 (C 5). 
127.68 (C 3). 128.07 (C 8),.132.92 (C 9). 133.80 (C 10)..144.58 (C 2). 
157.98 (CONH). 179.11 (COOH). 179.40 (COOH) 
MS (ES+): m/z 722.2 (MNa+) 
{(2-{( Carboxymethyl)[2-(alkylamino )-2-oxoethyl]amino }ethyl)[2-
(alkylamino )-2-oxoethyl]amino }acetic acid. 
4-[2- (2, 6-Dioxomorpholin -4-yl)ethyl]morpholin-2, 6-dione (EDTA 
dianhydride) ( 10 mmol), was combined with dry THF (20ml), under an 
inert atmosphere. Addition of amine (22 mmol), to this suspension 
was carried out over a 15 min period. Liquid amines were added 
dropwise, directly to the stirred solution. Solid amines, were dissolved 
in the minimum volume of dry THF before addition. The suspension 
was stirred for 6-8h. The solvent was then removed under reduced 
pressure, and the solid white residue was washed with water (3x20ml) 
and ether (3x50n11). The solid white product, was then dried under 
reduced pressure and characterised by elemental analysis and NMR. 
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{(2-{( Carboxymethyl)[2-((R)-( + )-1-(2-naphthyl)ethylamino )-2-
oxoethyl]amino}ethyl) [2-((R)-( + )-1-(2-naphthyl)ethylamino )-2-
oxoethyl]amino}acetic acid. 
[ 32] 
m. p. in excess of 250°C 
Anal. C34H3sN405.Na. 112 H20 calculated C, 64.8% H, 6.18% N, 8.88%. 
Found C, 65.06%, H, 6.18%, N, 8.95%. 
& ppm (CD30D): 22.93 (CH3), 49.05 (CH2NH), 52.86 (-N-CH2-COOH), 
59.45 (-N-CH2-CONH), 60.27 (Naph-CH-NH), 124.02 (C 6), 124.43 (C 
7), 125.50 (C 1), 126.01 (C 4), 127.30 (C 5), 127.65 (C 3), 127.99 (C 
8),.131.91 (C 9), 134.21 (C 10),.144.53 (C 2), 159.57 (CONH), 179.24 
(COOH). 
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{(2-{(Carboxymethyl) [2-( octylamino )-2-oxoethyl]amino }ethy1)[2-
( octylamino )-2-oxoethyl]amino }acetic acid. 
OH !-~ o~N~N~o j OH NH-r 
0 
[ 33] 
m.p. in excess of 250°C 
OH ppm (CD30D): 0.86 (6H, m, CH3). 1.27 (20H, m, -(CH2)5-). 1.5 (4H, 
m, CH2-CH3). 3.07 (4H, s, -HN-(CH2h-NH-). 3.23 (4H, t, J = 6Hz, HN-
CH2-). 3.52 (4H, s, -N-CH2-COOH). 3.56 (4H, s, -N-CH2-CONHR) 
MS (ES+): m/z 537.2 (MNa+) 
Anal. C25H5oN405.Na Calc. C, 58.08%, H, 9.37%, N, 10.42%, 
Found C, 58.93% H, 9.27% N, 10.56% 
{(2-{(Carboxymethy1)[2-(dodecylamino)-2-oxoethyl]amino}ethy1)[2-
( dodecylamino )-2-oxoethyl]amino }acetic acid. 
[ 34] 
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m. p. in excess of 250°C 
OH ppm (CD30D): 0.89 (6H, m, CH3), 1.32 (36H, m, -(CH2)g-), 1.53 (4H, 
m, CH2-CH3). 3.11 (4H, s, -HN-(CH2b-NH-). 3.24 (4H, t, J = 6Hz, HN-
CH2-), 3.54 (4H, s, -N-CH2-COOH). 3.61 (4H, s, -N-CH2-CONHR) 
MS (ES+): m/z 649.5 (MNa+) 
Anal. C34H66N406 calculated C, 65.14% H, 10.61% N, 8.94% Found C, 
65.27% H, 10.95% N, 8.92% 
{(2-{( Carboxymethyl)[2-(hexadecylamino )-2-
oxoethyl]amino}ethyl)[2-(hexadecylamino )-2-
oxoethyl]amino}acetic acid. 
[ 35] 
m. p. in excess of 250°C 
OH ppm (CD30D): 0.87 (6H, m, CH3). 1.34 (52H, m, -(CH2)13-). 1.51 
(4H, m, CH2-CH3). 3.13 (4H, s, -HN-(CH2h-NH-), 3.32 (4H, t, J = 6 Hz, 
HN-CH2-). 3.60 (4H, s, -N-CH2-COOH). 3.63 (4H, s, -N-CH2-CONHR) 
Anal. C42Hs2N406 calculated C, 68.25% H, 11.18% N, 7.58%. Found C, 
68.32% H, 11.34% N, 7.44% 
Zinc {(2-{( carboxymethyl) [2-( octylamino )-2-
oxoethyl]amino}ethyl)[2-(octylamino)-2-oxoethyl]amino}acetate. 
{(2-{ (Carboxymethyl) [2- ( octylamino)-2-oxoethyl] amino}ethyl) [2-
(octylamino)-2-oxoethyl]amino}acetic acid (0.1mmol). was combined 
with zinc (11) acetate (0.11 mmol), in purite water (50ml) and boiled 
under reflux for 6-8 h. The mixture was then cooled and filtered, the 
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filtrate was washed with water (3 x 30ml) and then dried under 
reduced pressure. The complex was characterised using l H NMR to 
observe changes from the free ligand. 
OH ppm (D20): 0.86 (6H, m, CH3), 1.27 (20H, m, -(CH2)5-), 1.5 (4H, m, 
CH2-CH3), 2.65 (2H, d, J = 10 Hz, -HN-CH2-CH2-NH), 2.86 (2H, d, J = 
10Hz, -HN-CH2-CH2-NH) 3.17 (4H, m, HN-CH2-), 3.38 (4H, d, J = -16 
Hz, -N-CH2-COOH), 3.44 (4H, d, J= -16Hz, -N-CH2-CONHR) 
MS (ES+): m/z 578.4(MH+) 
Anal C26H5oN405Zn.VzH20 calculated C, 53.01%, H, 8.73%, N, 9.51%, 
Found C, 53.41%, H, 9.02%, N, 9.67%, 
Zinc {(2-{( carboxymethyl)[2-( dodecylamino )-2-
oxoethyl]amino }ethyl) [2-( dodecylamino )-2-oxoethyl)amino }acetate. 
OH ppm (CD30D): 0.89 (6H, m, CH3), 1.32 (36H, m, -(CH2)g-), 1.53 (4H, 
m, CH2-CH3), 2.81 (2H, d, J = 9.5 Hz, -HN-CH2-CH2-NH), 3.05 (2H, d, 
J = 10Hz, -HN-CH2-CH2-NH), 3.34 (*H, m, HN-CH2-), 3.50 (4H, d, J = 
-15Hz, -N-CH2-COOH). 3.64 (4H, d, J= -15Hz, -N-CH2-CONHR). 
MS (ES+): m/z 691.9 (MNa+) 
Zinc {(2-{( carboxymethyl) [2-(hexadecylamino )-2-
oxoethyl)amino }ethy1)[2-(hexadecylamino )-2-
oxoethyl)amino}acetate. 
OH ppm (CD30D): 0.80 (6H, m, CH3). 1.21 (20H, m, -(CH2)5-). 1.43 (4H, 
m, CH2-CH3). 2.68 (2H, d, J = 10Hz, -HN-CH2-CH2-NH). 2.89 (2H, d, J 
= 10Hz, -HN-CH2-CH2-NH) 3.29 ( *H m, HN-CH2-). 3.38 (4H, d, J = -
16Hz, -N-CH2-COOH). 3.44 (4H, d, J= -16Hz, -N-CH2-CONHR) 
(* = peaks overlap with residual solvent signal preventing accurate 
integration.) 
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Appendix 1 
X=ray Structural Data for 
Olsrv205 
( 5= hexylpyridine= 2=carboxamide) 
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Structure 01 srv205 
Table I. Crystal data and structure refinement for 0Isrv205. 
Identification code 0Isrv205 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta= 28.58° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data I restraints I parameters 
Goodness-of-fit on F2 
Final R indices [l>2sigma(l)] 
R indices (all data) 
Extinction coefficient 
Largest diff. peak and hole 
C,2H12N02 
202.23 
I20(2) K 
0.71073 A 
Monoclinic 
P2(l)lc 
a= I4.07I6(l2) A 
b = 5.6413(5) A 
c = I5.I563(13) A 
I 141.87(17) A3 
4 
I.l76 Mg/m3 
0.08I mm-1 
428 
0.20 x O.I5 x O.I5 mm3 
1.52 to 28.58°. 
13= 108.364(2t. 
-I8<=h<=I8, -7<=k<=7, -20<=k=I9 
I2220 
29 I 0 [R(int) = 0.0796] 
99.4% 
None 
. and. 
Full-matrix least-squares on F2 
29IO I 0 I 208 
I.043 
RI = 0.0455, wR2 = 0.0993 
RI= 0.0836, wR2 = O.I2II 
0.300 and -0.265 e.A-3 
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Table 2. Atomic coordinates ( x I 04) and equivalent isotropic displacement parameters (A.2x I 03) 
for 01 srv205. U(eq) is defined as one third of the trace of the orthogonalized Uii tensor. 
X y z U(eq) 
0(3) 4170(1) 4510(2) 11791(1) 25(1) 
N(3) 4786(1) 1179(3) 11333(1) 22(1) 
N(l) 4041(1) 2542(2) 9520(1) 20(1) 
C(4) 3084( l) 5270(3) 8334( I) 19( 1) 
C(2) 3858(1) 3949(3) IOI65(1) 18(1) 
C(l) 4295(1) 3234(3) I1173(1) 18(1) 
C(3) 3305(I) 6017(3) 9947(1) 22(1) 
C(5) 2710(1) 5868(3) 7309(1) 22(1) 
C(9) 1055(1) 26I5(3) 5068(1) 22(1) 
C(6) 1996(1) 4008(3) 6719(1) 22( I) 
C(8) 2908(1) 6679(3) 9017(1) 23(1) 
C(IO) 1752(1) 4457(3) 5677(1) 2I (I) 
C(7) 3652(1) 32I8(3) 8631(1) 21(1) 
C(ll) 864(I) 3002(3) 4031(1) 24(1) 
C(12) 178(2) II37(4) 3429( I) 31 (1) 
Table 3. Bond lengths [A] and angles [0 ] for 0Isrv205. 
0(3)-C(1) I.2368(19) C(8)-C( 4 )-C(7) II6.95(14) 
N(3)-C(l) 1.332(2) C(8)-C(4)-C(5) I23.46(l5) 
N(I)-C(7) 1.341 (2) C(7)-C( 4 )-C(5) 1I9.58(I4) 
N(l)-C(2) I.345(2) N(l)-C(2)-C(3) 123.10(14) 
C(4)-C(8) I.387(2) N(1)-C(2)-C(I) II7.84(13) 
C(4)-C(7) 1.398(2) C(3 )-C(2)-C(l) I19.06(14) 
C(4)-C(5) 1.513(2) 0(3)-C(I)-N(3) 123.95(14) 
C(2)-C(3) I.384(2) 0(3 )-C( 1 )-C(2) I20.02(14) 
C(2)-C( I) 1.51I(2) N(3)-C(I)-C(2) I16.01(13) 
C(3)-C(8) 1.394(2) C(2)-C(3)-C(8) 118.90(15) 
C(5)-C(6) 1.532(2) C(4)-C(5)-C(6) 113.53(13) 
C(9)-C(IO) I.524(2) C( I 0)-C(9)-C( 1I) II3.39(14) 
C(9)-C(1I) 1.524(2) C( I O)-C(6)-C(5) II2.51(13) 
C(6)-C(10) 1.528(2) C(4)-C(8)-C(3) 119.46(15) 
C( 11 )-C(l2) 1.522(2) C(9)-C( 1 0)-C(6) I13.86(13) 
N (I )-C(7)-C( 4) I24.72(15) 
C(7)-N( I )-C(2) 116.86(14) C(l2)-C(II)-C(9) II3.07(14) 
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Table 4. Anisotropic displacement parameters (A2x I 03) for 01srv205. The anisotropic 
displacement factor exponent takes the form: -27t2[ h2 a*2U 11 + ... + 2 h k a* b* U12] 
Ull un U33 u23 U13 U12 
0(3) 30(1) 29( 1) 15(1) -4(1) 6(1) 3(1) 
N(3) 25(1) 27(1) 13(1) 1(1) 4(1) 5(1) 
N(l) 21 ( 1) 22( 1) 16(1) -2(1) 4(1) 2(1) 
C(4) 17(1) 22(1) 17( 1) 2(1) 3(1) -3(1) 
C(2) 16( 1) 21(1) 16(1) 0(1) 3(1) -2(1) 
C(l) 17(1) 23(1) 14(1) -1 (1) 3(1) -3(1) 
C(3) 26(1) 22(1) 19( 1) -4(1) 6(1) 2(1) 
C(5) 24(1) 23(1) 16( 1) 3(1) 2(1) 0(1) 
C(9) 22(1) 24(1) 17(1) 2(1) 4(1) -1(1) 
C(6) 22(1) 25(1) 18(1) 3(1) 3(1) -1(1) 
C(8) 23(1) 20(1) 24(1) 1(1) 4(1) 4(1) 
C(IO) 21(1) 22(1) 17(1) 2(1) 3(1) 1 (1) 
C(7) 23(1) 25(1) 15(1) -2(1) 5(1) 3(1) 
C(11) 28(1) 24(1) 18(1) 1 (1) 6(1) -1(1) 
C(12) 37(1) 33(1) 20(1) -4(1) 6(1) -6(1) 
Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2x 10 3) 
for 0 I srv205. 
X y z U(eq) 
H(3) 2540(13) 8140(30) 8855(12) 24(5) 
H(l2) 553(14) 4580(30) 3842(13) 28(5) 
H(l1) 1360(13) 1010(30) 5247(12) 25(5) 
H(7) 2297(13) 2410(30) 6852(12) 24(5) 
H(9) 2403(15) 4450(30) 5502(13) 32(5) 
H(l6) 454(16) -420(40) 3572(15) 45(6) 
H(2) 3216(14) 6930(30) 10448(14) 31(5) 
H(l) 3806(14) 2220(30) 8188(14) 34(5) 
H(8) 1455(13) 6080(30) 5531(12) 24(5) 
H(l3) 1525(15) 2980(30) 3907(13) 35(5) 
H(6) 1348(14) 3990(30) 6896(13) 29(5) 
H(14) -498(16) 1130(40) 3546(14) 40(6) 
H(4) 2406(14) 7470(40) 7241(13) 32(5) 
H(5) 3319(15) 6050(30) 7087(14) 35(5) 
H(IO) 406(14) 2560(30) 5192(13) 32(5) 
H(l5) 87(17) 1390(40) 2776(16) 49(6) 
H(l8) 4884(15) 420(40) 10847(15) 37(6) 
H(17) 5048(16) 690(40) 11925(16) 43(6) 
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Data used in the calculation of CMC and CAC 
values. 
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Pyrldine-2-methylamine compounds [ 29 ] and [ 30 J 
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EDTA Diamide Compounds I 33 ], I 34] and ( 35) 
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Co'iUI.rses Lectures and Seminwrs 
Attended by the Author 
O~t©belr 1999 = Oct~ber 2002 
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Organometallics in Synthesis 
Separation Methods 
Practical Spectroscopy 
Mass Spectroscopy and NMR Techniques 
Jl)epartmentall Seminu® Attended 1999/2002 
1999 
October 13 
October 20 
November 10 
November 18 
November 23 
December 8 
2000 
January 19 
Professor G. Fleet, University of Oxford 
Sugar Lactone and Amino Acids 
ProfessorS. Lincoln, University of Adelaide 
Aspects of Complexation and Supramolecular 
Chemistry 
Dr. I. Samuel, Department of Physics, University of 
Durham 
Improving Organic Light Emitting Diodes by Molecular, 
Optical and Device Design 
Dr. G. Siligardi, Kings College London 
The Use of Circular Dichrosim to Detect and 
Characterise Biomolecular Interactions in Solution. 
Professor B. Caddy 
Trace evidence - a challenge for the forensic scientist 
Professor D. Crout, Department of Chemistry, 
University of Warwick 
More than Simply Sweet: Carbohydrates in Medicine 
and Biology 
Dr. P.R. Fielden, UMIST 
Miniaturised Chemical Analysis (Lab-on-a-Chip): 
Functional or Merely Fashionable? 
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January 26 
January 25 
March 1 
March 8 
May5 
October 25 
November 7 
November 8 
November 29 
December 5 
December 6 
Professor S. Flisch, University of Edinburgh 
The challenges involved in protein glycosylation -
synthesis of glycan chains and selective attachment to 
proteins 
Professor B. Meijer 
From Supramolecular Architecture Towards 
Functional Materials 
Professor D. Tildsley, Unilever (Head of Research) 
Computer Simulation of Interfaces: Fact and Friction 
Professor J. Courtieu, Universite de Paris-Sud, Orsay 
Chiral Recognition through NMR in Liquid Crystal 
Solvents: an Order Affair 
Professor R. Hochstrasser, University Pennsylvania, 
USA 
Ultrafast Molecular and Protein Dynamics seen 
through their Vibrations 
Dr S.F. Campbell, Former Senior Vice President of 
Pfizer 
Science, art and drug discovery. A personal 
perspective 
Dr C. Ludman, Durham University 
Explosions - A demonstration lecture 
J.P.L. Cox, Bath University 
Cosmic: a universal, DNA-based language for 
communicating with aliens and other intelligent 
lifeforms 
Professor T. George Truscott, University of Keele 
Life, Death and the Carotenoids 
Dr D. Kelly, Cardiff University 
The chemistry of sexual attraction 
Professor Richard Compton, University of Oxford 
Dual activation approaches to electroanalysis: 
ultrasound, microwaves and laser activation 
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2001 
January 10 
January 23 
January 24 
February 21 
October 9 
October 31 
November 6 
November 20 
November 21 
November 27 
December 5 
ProfessorS. P. Armes 
School of Chemistry, Physics and Environmental 
Science, University of Sussex 
Micelles, reversed micelles and shell-crosslinked 
micelles based on tertiary amine methacrylates 
Professor C. Sterling, Sheffield University 
Why should the public bother with science anyway? 
Dr Andrew de Mello, Department of Chemistry, 
Imperial College, London 
Chemical Integrated Circuits: organic synthesis and 
analysis on a small scale 
Professor Rob Richardson Department of Physics, 
University of Bristol 
Liquid Crystals of All Shapes and Sizes 
Dr Roy S Lehrle, Birmingham 
Forensics, Fakes and Failures 
Dr Colin Raston, School of Chemistry, Univ of Leeds 
Towards benign supramolecular chemistry: synthesis 
- self organisation 
Dr Cliff Ludman, Durham University 
Explosions - a demonstration lecture 
Professor Peter Atkins 
A Century of Physical Chemistry 
Dr Roy Copely, GlaxoSmithKline 
Crystallography in the Pharmaceutical Industry 
Professor Ian GM Cowie, Herriot-Watt University 
Cellulose - An old polymer with new applications 
In association with The North East Polymer 
Association 
Dr Mike Eaton, Celltech 
Drugs of the Future 
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2002 
February 26 Dr Mike Griffin, Forensic Science Service, Metropolitan 
Police 
Smack, Crack, Speed and Weed: A forensic chemists 
tale 
March 12 Professor David Williams, Cardiff 
Beer and Health: 7000 years of history 
Graduate Colloquia, comprising talks by third-year postgraduate 
students, have been attended each year. 
Conferences Attended 
Stereochemistry at Sheffield 
University of Sheffield 1999 
RSC Organic Reaction Mechanisms Group. Winter Meeting 2002 
"Mechanistic Aspects of the Design of Bioactive Materials" 
University of Manchester January 3 2002 
RSC Perkin Group Meeting 
University of York April 2002 
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